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CHAPTER 1 
 
INTRODUCTION 
 
Post-traumatic stress disorder 
 
Clinical features and current therapies 
Post-traumatic stress disorder (PTSD) is a psychiatric condition that manifests in a subset 
of individuals after experiencing a traumatic event(s) (1). PTSD symptoms are categorized into 
the following four diagnostic criteria: intrusion, including flashbacks and nightmares; avoidance; 
negative alterations in cognition and mood; and alterations in arousal, such as hypervigilance and 
poor sleep (1-3). While the lifetime prevalence of PTSD in the general population lies on the 
order of 6.8% (4, 5) estimates reach as high as 30.9% among subpopulations at particular risk for 
trauma such as war veterans (6). PTSD symptoms usually begin within one to six months after 
the trauma, but can last for decades and are associated with significant increases in health care 
use and costs (7, 8). Current treatments include both psychotherapy, such as exposure therapy 
and cognitive behavioral therapy (9), and medication (10-12). The selective serotonin reuptake 
inhibitors (SSRIs) sertraline (Zoloft) and paroxetine (Paxil) represent the front-line 
pharmacological treatment for PTSD patients, but these drugs are only partially effective and 
rarely result in full remission of symptoms (10). Sleep disturbances and nightmares are 
particularly resistant to treatment with currently available therapies, and constitute some of the 
most prevalent and disruptive symptoms in PTSD patients (2, 11). Thus, there is a critical need 
to develop novel therapeutic approaches for better management, remission, or prevention of 
PTSD. 
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Role of emotional memory  
Collectively, PTSD symptoms represent a persistent, inextinguishable stress response 
initiated by the traumatic event. From an evolutionary perspective, this response can be an 
adaptive means of enhancing survival when confronted with threatening or fearful stimuli (13, 
14). By augmenting associative memory for contextual cues surrounding the threat, activation of 
the stress response can also compel avoidance or vigilance behaviors that prevent future 
encounters with the same danger (13, 14). Indeed, multiple studies have demonstrated that 
memories with an affective component are more vivid and durable than other memories (15). 
This response becomes maladaptive when the dangers associated with the traumatic event no 
longer pose a threat. Enhanced implicit and explicit memory for the traumatic event, as well as 
impaired extinction of this memory and generalization of associated cues, then contribute to the 
maintenance of chronic symptoms, leading to PTSD (14, 16-20). Thus, PTSD can be 
conceptualized as a disorder of learning and memory, the proximal cause of which is the 
acquisition and consolidation of traumatic memory and related negative emotions (14, 16-20). 
Mounting empirical evidence demonstrates PTSD-related disruptions in multiple domains 
of emotional memory that likely contribute to susceptibility for the disorder or the maintenance 
of symptoms (21-28). These deficits in PTSD patients are linked to structural and functional 
alterations in various subregions of the prefrontal cortex (PFC), hippocampus, and amygdala, 
brain areas known to be important for both memory formation and the regulation of emotion (29, 
30). Specifically, PTSD symptoms are associated with altered size and function of the 
hippocampus, impaired activation of the PFC, and a corresponding disinhibition of amygdala 
activity (29, 30). This pathophysiology may contribute to PTSD symptom development by 
promoting the formation and maintenance of negative emotional memory during and 
 3 
immediately after the trauma, or by impairing the successful extinction of these memories once 
formed (21-25, 31). 
 
Novel treatment strategies 
A novel strategy for the treatment of PTSD, therefore, is to modulate emotional memory 
formation and maintenance in order to attenuate explicit or implicit recall for the traumatic event 
(14, 16-18, 31, 32). Among neuropsychiatric disorders, PTSD is uniquely well suited to this 
approach because its diagnosis is contingent upon a requisite environmental component, the 
traumatic event, which signals the onset of symptoms (1, 13). Pharmacological interventions that 
promote or inhibit emotional memory formation and maintenance are hypothesized to have 
therapeutic potential at different points in the timeline of PTSD symptom progression. Based on 
the learning hypothesis of PTSD, these strategies can be broadly classified into four groups: 1) 
compounds that inhibit the acquisition or consolidation of emotional memory formation during 
or immediately after trauma, 2) compounds that inhibit the reconsolidation of emotional memory 
during subsequent recall of events related to the trauma, 3) compounds that facilitate the 
extinction of emotional memory associated with the trauma, and 4) compounds that attenuate the 
general expression of anxious behaviors (Figure 1). 
Recent successes with both pharmacotherapeutic and psychotherapeutic interventions 
have provided clinical proof of concept validation for some of these approaches (14, 18, 31, 32), 
but the limited availability of pharmacological agents that potently and selectively target 
molecular mediators of emotional learning and memory represents a hurdle to the clinical 
advancement of new treatments. Furthermore, the initial discovery and development of 
pharmacological agents that manipulate emotional memory is performed exclusively in the 
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Figure 1. Opportunities for intervention in symptom progression after trauma. These 
strategies can be broadly classified into four groups: 1) compounds that inhibit the acquisition or 
consolidation of emotional memory formation during or immediately after trauma, 2) compounds 
that inhibit the reconsolidation of emotional memory during subsequent recall of events related 
to the trauma, 3) compounds that facilitate the extinction of emotional memory associated with 
the trauma, and 4) compounds that attenuate the general expression of anxious behaviors. 
 
preclinical arena, highlighting the need for an animal model of traumatic stress with robust 
predictive, face, and construct validity. 
 
Rodent behavioral assays of emotional memory  
Traditionally, researchers have employed rodent models of aversive associative 
conditioning, such as auditory cued and contextual conditioned fear (CF), fear-potentiated startle 
(FPS), inhibitory avoidance (IA), and conditioned taste aversion (CTA), to probe the 
mechanisms underpinning emotional memory formation and maintenance. Multiple studies 
employing these and other paradigms have revealed that encoding of emotionally valenced 
information occurs in distinct phases. Initial acquisition of the memory is followed by 
consolidation; subsequent recall of the memory can lead to either reconsolidation or extinction 
depending on the duration of and context surrounding the recall event (33). Each of these steps is 
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mediated by distinct molecular mechanisms which take place within and between various 
subregions of the thalamus, PFC, hippocampus, and amygdala (18, 33, 34). 
In general, the successful acquisition, consolidation, and expression of threat-based 
memory requires convergent excitatory signaling in the amygdala which is contextualized by 
hippocampal input, and gated by PFC afferents to inhibitory interneurons (Figure 2). The 
induction of long term potentiation (LTP) at thalamic and sensory cortical synapses in the 
basolateral amygdala (BLA) represents a well-established neurophysiological correlate of 
emotional memory acquisition (18, 33, 35). This initial excitation of primary BLA neurons 
during acquisition is followed by the induction of several mechanisms promoting the 
consolidation of emotional memory, which include the activation of intracellular signaling 
pathways such as extracellular receptor kinase 1/2 (ERK 1/2) phosphorylation, culminating in 
transcriptional activation and new protein synthesis (33). For example, activation of early growth 
response protein 1 (EGR-1) in the amygdala is known to be required for the formation of new 
threat-based memories (33). EGR-1 is an immediate early gene and transcription factor that lies 
downstream of ERK1/2 activation, and induces the rapid expression of a host of genes involved 
in synaptic remodeling (33). Specifically, the protein products of these genes are involved in the 
maintenance of amygdala LTP and morphological changes such as increased dendritic spine size 
and density (33, 36, 37). Reactivation of emotional memories through passive recall returns these 
synapses to a labile state during which reconsolidation or extinction can take place (37-39). The 
cellular mechanisms that subserve reconsolidation have yet to be fully delineated, but early work 
suggests that this process shares some of the same molecular mediators with initial consolidation, 
although reconsolidation may be mediated by post-synaptic rather than pre-synaptic 
modifications (37-39). Repeated recall of an emotional memory without further reinforcement of 
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the initial association leads to extinction (37, 39). Extinction is partially mediated by activation 
of the infralimbic region of the PFC (IL) which attenuates amygdala output through excitation of 
inhibitory intercalated cells (ITC) and through long term depression (LTD) or depotentation of 
thalamic and cortical synapses in the BLA that had previously undergone LTP (40-45). Finally, 
the expression of threat responses related to the emotional memory requires BLA activation of 
output neurons in the central amygdala (CeA) and the bed nucleus of the stria terminalis (BNST), 
which is facilitated by persistent activity in the prelimbic region of the PFC (PL) (46-50). 
Throughout all of these processes, hippocampal activation and long-term plasticity provides 
context specificity (51). 
It is important to note that the neural circuitry involved in emotional memory encoding 
corresponds to the same brain regions found in functional neuroimaging studies to be altered in 
PTSD patients (52). Reduced hippocampal volume is a well-established finding in PTSD patients 
that likely results in poor contextualization of emotional memory, a symptom of PTSD patients 
that leads to inappropriate stress reactions (52). Reduced activation of the ventromedial PFC, a 
brain region analogous to the IL in rodents, has also been reported multiple times in PTSD 
patients, and is associated with enhanced expression and poor extinction of threat-based 
memories (52). Impaired PFC activation also correlates with disinhibition of the amygdala in 
PTSD patients, resulting in hyperactivity of this structure and associated behavioral outcomes 
that include hyperarousal symptoms and sleep disturbances (52).  
Using the rodent behavioral assays mentioned above to manipulate the function of these 
circuits, multiple compounds that target various neurotransmitter systems as well as broad 
cellular functions such as gene transcription and protein synthesis have been discovered that 
affect the acquisition, consolidation, reconsolidation, extinction, and/or expression of learned 
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threat behavior (53). However, there are two important caveats to the interpretation of 
experimental results gleaned from pharmacological manipulation of the rodent response to 
aversive associative conditioning. First, it is not known whether the acquisition, consolidation, 
and recall of a rodent’s memory for threatening stimuli fully encompass the complexity of 
emotional memory formation and maintenance in humans (54). Second, these aversive learning 
paradigms likely represent normal associative learning after a stressful event, not necessarily the 
pathological overconsolidation of emotional memory that occurs in PTSD patients who have 
experienced traumatic stress. While the molecular mechanisms that subserve normal threat 
learning are likely involved in pathological processes as well, and thus provide valuable insight, 
the physiological and behavioral consequences of trauma are different from those of mild stress 
in both rodents and humans. It will be critical, therefore, to test novel pharmacological 
interventions in rodent models that employ more severe stressors akin to the trauma experienced 
by an individual who goes on to develop PTSD. 
 
Rodent models of traumatic stress 
Putative rodent models of traumatic stress include underwater trauma (55), predator scent 
stress (56), social conflict (57), learned helplessness (58), and Single Prolonged Stress (SPS) 
(59). Each of these models recapitulates some of the physiological and behavioral alterations 
found in PTSD patients, and offers new insight into the pathophysiology of the disorder. Each 
model has also been used to test novel pharmacological interventions that could prevent or 
ameliorate these changes (55-59).  
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Figure 2. Neural threat circuitry. Adapted from (51). Acquisition, consolidation, and 
expression of threat-based memory requires convergent excitatory signaling in the amygdala 
which is contextualized by hippocampal input, and gated by PFC afferents to inhibitory 
interneurons. PL: prelimbic cortex; IL: infralimbic cortex; BLA: basolateral amygdala; CeA: 
central amygdala; ITC: intercalated inhibitory cells. 
 
 
Of these models, SPS exhibits strong face and construct validity (Table 1). SPS is 
induced by a single presentation of three classically used rodent stressors: two hours of restraint, 
followed by twenty minutes of forced swim and then exposure to ether inhalation until anesthesia 
(60). SPS achieves a level of traumatic stress that surmounts the stress that would be induced by 
each individual stressor alone. In this way, SPS represents a traumatic experience for rodents 
consisting of an acute physical and psychological insult culminating in simulated death through 
loss of consciousness. SPS treatment mounts a dramatic stress response in rodents as measured 
by increases in circulating corticosterone, the rodent analogue of the human stress hormone, 
cortisol (60). Similar to the pathophysiology of PTSD patients, rats and mice which have 
undergone SPS subsequently display enhanced negative feedback of the hypothalamic-pituitary-
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adrenal (HPA) axis (60), cell death in the hippocampus (61-64), and reduced excitatory tone in 
the PFC (65). SPS rats also demonstrate increased hippocampal expression of FK506-binding 
protein 51 (FKBP5), an early stress-responsive gene that acts as a co-chaperone of the 
glucocorticoid receptor complex (66). Importantly, genetic variability and altered expression of 
FKBP5 has been associated with PTSD risk, diagnosis, and treatment (67-69). 
At the level of behavior, rodents exposed to SPS show increased startle reactivity (70-
75), augmented threat responding in aversive associative conditioning assays (70-75), and 
impaired extinction of threat-related behaviors (76-81), consistent with disruption of normal 
emotional memory formation and maintenance. The behavioral alterations induced by SPS in 
rats have been found to be sensitive to SSRI treatment (82), suggesting that this model may also 
exhibit predictive validity. Recently, it was also found that SPS results in increased cerebrospinal 
fluid (CSF) levels of the excitatory neurotransmitter, glutamate, caused in part by reduced 
hippocampal expression of the glutamate transporters GLAST and GLT-1 (83). Together, these 
findings indicate combined dysfunction of the serotonergic and glutamatergic neurotransmitter 
systems that could conspire to induce short and long-term PTSD-like behavioral alterations 
spurred by the persistent expression of traumatic memory. The SPS model, therefore, may be a 
viable means of discovering novel interventions to prevent or treat PTSD by modulating 
emotional memory formation and maintenance before, during, or after trauma.  
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Table 1. Summary of effects of SPS 
Effect of SPS Reference 
Increased expression of norepinephrine synthesizing enzyme tyrosine hydroxylase 
(TH) in locus coeruleus (LC) Sabban EL, et al. (2015) 
Increased CF expression and anxiety-like behavior in open field and EPM Qiu ZK, et al. (2015) 
Altered cocaine intake and reduced dopamine content in the striatum Enman NM, et al. (2015) 
Increased CSF glutamate and decreased glutamate transporter GLAST/GLT-1 
expression;  increased CF expression and anxiety-like behavior in open field Feng D, et al. (2015) 
Increased neuronal apoptosis in PFC Li X, et al. (2015) 
Increased activity-dependent metabolites in amygdala Han F, et al. (2015) 
Increased CF expression and impaired extinction Keller SM, et al. (2015) 
Impaired reversal learning George SA, et al. (2015) 
Increased glucocorticoid receptor (GR) levels in hippocampus and impaired CF 
extinction Keller SM, et al. (2015) 
Increased cocaine-mediated hyperlocomotion Eagle AL, et al. (2015) 
Anxiety-like behavior in open field and EPM Wang HN, et al. (2015) 
Anxiety-like behavior in EPM Sabban EL, et al. (2015) 
Anxiety-like behavior in open field, EPM, light-dark box; radial arm maze deficits; 
increased plasma corticosterone; decreased histone acetylation Solanki N, et al. (2015) 
Increased GR levels and PKC phosphorylation in PFC Wen L, et al. (2015) 
Impaired CF extinction Eskandarian S, et al. (2015) 
Impaired CF extinction; increased GR expression in PFC and hippocampus George, et al. (2015) 
Apoptosis in PFC; impaired Morris Water Maze performance Yu B, et al. (2014) 
Depression-like behavior in FST and anxiety-like behavior in open field and EPM Ji LL, et al. (2014) 
Increased plasma corticosterone, corticotrophin-releasing hormone (CRH) mRNA in 
mediobasal hypothalamus, and TH and dopamine-β hydroxylase mRNA in LC Serova LI, et al. (2014) 
Increased CRH and FK506-binding protein 5 (FKBP5) mRNA in hippocampus and 
hypothalamus Laukova M, et al. (2014) 
Decreased body weight; reduced sucrose preference; increased plasma 
corticosterone; nxiety-like behavior in open field and EPM Lee B, et al. (2014) 
Increased CF expression and anxiety-like behavior in EPM Miao YL, et al. (2014) 
Decreased GR and mineralocorticoid receptor (MR) expression in amygdala Han F, et al. (2014) 
Increased phosphorylation of ERK1/2 in PFC Qi J, et al. (2014) 
Increased CF expression and anxiety-like behavior in EPM; decreased 
phosphorylation of ERK1/2 in hippocampus Nie H, et al. (2014) 
Depression-like behavior in FST and anxiety-like behavior in open field and EPM Serova, et al. (2014) 
Increased GR expression in PFC and hippocampus George SA, et al. (2013) 
Anxiety-like behavior in open field and EPM Peng Z, et al. (2013) 
Anxiety-like behavior in open field and EPM Serova LI, et al. (2013) 
Apoptosis and reduced phosphorylation of ERK1/2 in hippocampus Peng Z, et al. (2013) 
Increased evoked, reduced spontaneous firing of LC neurons George SA, et al. (2013) 
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Increased GR expression and PKB phosphorylation in hippocampus Eagle AL, et al. (2013) 
Increased IA and acoustic startle response Ganon-Elazar E, et al. (2012) 
Decreased Ca
2+
/calmodulin kinase IIα (CaMKIIα) expression in PFC Wen Y, et al. (2012) 
Altered CaMKIIα expression in dorsal raphe Xie H, et al. (2012) 
Increased 5-HT1A receptor expression in dorsal raphe Luo FF, et al. (2011) 
Altered MR and GR expression in LC Li M, et al. (2011) 
Increased BDNF and tyrosine kinase B (TrkB) receptor expression in hippocampus Takei S, et al. (2011) 
Increased phosphorylation of ERK1/2 and apoptosis in amygdala Liu H, et al. (2010) 
Increased CF expression and impaired extinction; increased GlyT1 mRNA in 
hippocampus Yamamoto S, et al. (2010) 
Increased CF expression and impaired extinction; increased GlyT1 mRNA in 
hippocampus Iwamoto Y, et al. (2007) 
Increased CF expression Takahashi T, et al. (2006) 
Enhanced negative feedback of HPA axis Liberzon I, et al. (1999) 
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Mechanisms of emotional memory formation and maintenance 
 
Glutamate-mediated emotional memory  
Over the past several years, ionotropic and metabotropic glutamate receptors (iGluRs and 
mGluRs) have emerged as key regulators of the molecular, synaptic, and behavioral correlates of 
emotional memory formation and maintenance (84). During memory encoding related to 
stressful stimuli, glutamate acts as the primary excitatory neurotransmitter via activation of 
postsynaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-Methyl-D-
aspartate (NMDA) iGluRs as well as pre and postsynaptic mGluRs of various subtypes (84, 85). 
NMDA receptor activation, in particular through its induction of synaptic plasticity, is known to 
be a requisite component of the cellular and behavioral correlates of emotional memory 
acquisition, consolidation, reconsolidation, extinction, and expression (33, 35).  
The facilitation of NMDA receptor-mediated extinction represents a particularly 
promising approach for the treatment of individuals with PTSD. This approach involves the 
pairing of a drug treatment with exposure-based psychotherapy to pharmacologically facilitate 
extinction learning, leading to remission of symptoms (86). Compounds that activate the NMDA 
receptor result in accelerated extinction of threat responses in several preclinical models of 
PTSD symptoms, pointing to the therapeutic potential of targeting this receptor in conjunction 
with exposure therapy. Unfortunately, despite their critical role in every step of emotional 
memory formation, direct targeting of NMDA receptors has limited clinical utility due to the 
potential for severe adverse effects (87, 88). NMDA receptor activation can be achieved with 
therapeutic index, however, using D-cycloserine (DCS), a partial agonist of the strychnine-
insensitive glycine binding (GlyB) site on the NMDA receptor. DCS has been shown to facilitate 
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the extinction of conditioned fear (CF), a rodent behavioral assay analogous to exposure therapy 
(86). Based on these data, recent clinical experiments were undertaken demonstrating modest 
efficacy of DCS in augmenting the beneficial effects of exposure therapy in PTSD patients (89). 
Although these studies offer proof-of-concept validation for this therapeutic approach, other 
studies employing a similar strategy in PTSD patients found DCS to have no effect or to have a 
negative effect on recovery (90). These discrepant results are likely due to the fact that DCS, a 
partial agonist for the GlyB site, can actually act as an antagonist of NMDAR activity in the 
presence of high synaptic concentrations of the endogenous full agonist, glycine (91). 
Selective inhibition of the Glycine Transporter 1 (GlyT1) offers an alternative approach 
for the indirect modulation of NMDA receptors. Under normal conditions, the GlyB site on the 
NMDA receptor is not saturated due to the tightly controlled regulation of synaptic glycine levels 
by GlyT1, expressed in a distribution pattern that closely overlaps with NMDA receptor 
expression in the cortex and limbic regions of the brain (92). Previous studies have demonstrated 
that selective inhibitors of GlyT1 can increase synaptic glycine levels sufficiently to produce 
enhanced NMDA receptor function in preclinical rodent models (93). Recently, we have reported 
the development and characterization of a novel series of GlyT1 inhibitors, represented by 
ACPPBII, (2-amino-4-chloro-N-((4-phenyl-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamide), 
with suitable bioavailability, brain penetration, and physical properties for extensive 
characterization in vivo (94). Selective inhibition of GlyT1 by ACPPBII may provide a novel 
target for enhancing the therapeutic effects of exposure therapy in PTSD patients. Studies aimed 
at addressing this question were undertaken, and are presented in Appendix A. However, due to 
adverse effects that precluded the interpretation of these data (discussed in Chapter 4), we sought 
alternative routes to pharmacologically modulate NMDA receptor-dependent emotional memory.  
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Indirect modulation of NMDA receptor activity and its downstream molecular, synaptic, 
and behavioral effects can also be achieved through activation or inhibition of certain mGluRs. 
Recent evidence further supports a role for mGluRs in mediating emotional learning independent 
of their coupling to NMDA receptor-mediated signaling. Thus, targeting mGluRs as a means of 
altering traumatic memory formation and maintenance may have the potential to treat or possibly 
prevent PTSD symptoms. 
mGluRs are part of a subfamily of neuromodulatory G protein-coupled receptors 
(GPCRs) divided into three groups based on sequence homology, synaptic localization, and G 
protein coupling (for an in-depth review of receptor pharmacology and function see (95)). Group 
I includes mGluR1 and mGluR5, Group II includes mGluR2 and mGluR3, and Group III includes 
mGluR4, mGluR6, mGluR7, and mGluR8 (95). 
The Group I mGluRs are predominantly postsynaptic (95, 96), and exhibit high 
expression in PFC, amygdala, and hippocampus (96, 97) (Figure 3). Both mGluR1 and mGluR5 
couple to the Gαq/11 subtype of G proteins, activation of which leads to the induction of classical 
intracellular signaling pathways including phospholipase Cβ activation, formation of inositol 
1,4,5-trisphosphate (IP3), intracellular calcium mobilization, and activation of protein kinase C 
(PKC) (95). Importantly, mGluR1 and mGluR5 agonism has also been shown to increase activity 
in the mitogen-activated protein kinase/extracellular receptor kinase (MAPK/ERK) pathway, and 
the mammalian target of rapamycin (mTOR)/p70 S6 kinase pathway, leading to alterations in 
gene expression, protein synthesis, and synaptic plasticity particularly relevant to the formation 
and maintenance of emotional memories (33, 95, 98). In addition, both mGluR1 and mGluR5 
have been shown to be structurally and functionally linked to the NMDA receptor (99-104) such 
that mGluR1 or mGluR5 activation can promote, and its antagonism or genetic deletion can  
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Figure 3. Ionotropic and group I mGluR receptor signaling. Adapted from (105). Group I 
mGluRs are predominantly postsynaptic and couple to the Gαq/11 subtype of G proteins, 
activation of which leads to the induction of classical intracellular signaling pathways including 
phospholipase Cβ activation, formation of inositol 1,4,5-trisphosphate (IP3), intracellular 
calcium mobilization, and activation of protein kinase C (PKC). Both mGluR1 and mGluR5 have 
been shown to be structurally and functionally linked to the NMDA receptor. Arrow indicates a 
known allosteric binding site within the transmembrane domain. 
 
inhibit, NMDA receptor-dependent LTP and LTD in multiple brain regions (99, 103, 106-110). 
Based on these initial findings, several studies have gone on to demonstrate that more selective 
mGluR1 or mGluR5 modulation is sufficient to alter synaptic correlates of emotional memory 
formation and maintenance with measurable behavioral consequences (42, 111-151). 
The Group II mGluRs are generally localized to presynaptic terminals in several brain 
regions including the PFC, amygdala, and hippocampus (152, 153) where they function as 
autoreceptors or heteroreceptors to inhibit glutamate and other neurotransmitter release (95). 
Unlike the Group I mGluRs, mGluR2 and mGluR3 couple to the Gi/o subtype of G proteins 
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leading to inhibition of adenylyl cyclase and liberation of the Gβγ subunit (95). However, both 
mGluR2 and mGluR3 have also been found to be expressed postsynaptically (154, 155) where 
their activation causes hyperpolarization of postsynaptic neurons (154). Additionally, mGluR2/3 
antagonists have been shown to increase mTOR signaling in the PFC, indicating a negative 
coupling of these receptors to the MAPK/ERK and mTOR/p70 S6 kinase pathways (156). 
mGluR2 and mGluR3 modulate NMDA receptor function directly (157-159), and indirectly 
through alteration of presynaptic glutamate release (160). Furthermore, activation of the Group II 
mGluRs has been shown to enhance LTD and inhibit LTP in both NMDA receptor-dependent 
and independent manners in multiple brain regions including the cortex, hippocampus, and 
amygdala (161-175) with relevant effects on behavioral measures of emotional memory (176-
196). 
Similar to Group II, Group III mGluRs reside primarily in presynaptic terminals, and 
generally act to inhibit neurotransmitter release through coupling to the Gi/o subtype of G 
proteins (95), although Group III-mediated signaling through the MAPK and phosphatidyl 
inositol 3-kinase (PI3K) pathways has also been reported (197). Group III mGluRs exhibit 
diverse expression in the brain. mGluR4 and mGluR8 are both found in relatively low levels in 
the cortex, hippocampus, and amygdala (198, 199). mGluR7 is expressed throughout the brain, 
but has a very low affinity for glutamate (199). mGluR6, unlike the other mGluRs in this group, 
is primarily postsynaptic, and its expression is restricted almost entirely to the retina (199). 
Consistent with its expression profile, mGluR6 has not yet been shown to be involved in 
emotional learning and memory. Together, each of the other Group III mGluRs has been shown 
to be involved in NMDA receptor-dependent and independent plasticity in the hippocampus 
(199) and amygdala (200), and to affect emotional memory encoding (201-220). 
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Developing selective ligands represents a major hurdle to delineating the specific role of 
each mGluR subtype in modulating emotional memory formation and maintenance. Traditional 
methods of compound development, in which displacement of the endogenous ligand was the 
primary endpoint, restricted discovery efforts to compounds that bind the orthosteric site of a 
given receptor (221). In the case of many GPCRs including mGluRs, however, these sites are 
highly conserved between subtypes, rendering orthosteric ligands largely non-selective (221). 
Over the past several years, new screening methods and chemical optimization techniques have 
increasingly allowed for the discovery of small molecules that bind outside the orthosteric site of 
mGluRs and other GPCRs (221). By binding to less highly conserved regions of the receptor, 
often in the transmembrane domain, these allosteric ligands generally exhibit greater selectivity 
for specific GPCR subtypes (221). Allosteric ligands have been discovered that are capable of 
modulating the GPCR response to orthosteric agonists without having any intrinsic activity 
themselves; compounds that potentiate receptor response have been named positive allosteric 
modulators (PAMs) and compounds that inhibit the response have been named negative 
allosteric modulators (NAMs) (221). To date, multiple PAMs and NAMs have been developed 
that selectively target specific mGluR subtypes with little or no off-target activity at other 
GPCRs (95, 221). In addition, many of these selective compounds have been optimized for in 
vivo administration, enabling studies aimed at determining the effect of specifically targeting 
each mGluR subtype on the formation and maintenance of threat-related behaviors in mice and 
rats (95, 221). 
Due to the significant involvement of mGluR5 in emotional learning and memory, PAMs 
and NAMs for this receptor may be particularly useful for the treatment of PTSD. As mentioned 
above, mGluR5 canonically couples to the Gαq/11 subtype of G proteins; when activated by 
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stress-induced glutamate release, mGluR5 ultimately leads to the induction of downstream 
effectors that mediate synaptic remodeling and memory formation/maintenance (Figure 4). Many 
of these downstream signaling molecules lie also in the pathway that is activated by NMDA 
receptors, offering an indirect means of targeting the NMDA receptor for therapeutic purposes. 
This process is also dependent on new protein synthesis, and can be blocked by protein synthesis 
inhibitors such as anisomycin (33). Importantly, pharmacological inhibition of mGluR5 can also 
reduce new protein synthesis (222), and as mentioned above, attenuate the neural and behavioral 
correlates of emotional memory formation. 
One of the first studies to specifically implicate mGluR5 in the neural underpinnings of 
emotional learning and memory demonstrated that both acquisition/consolidation and extinction 
of combined cued and contextual CF could increase mGluR5 expression in the hippocampus 
(138). These experiments were quickly followed by several reports that 2-methyl-6-
(phenylethynyl)pyridine (MPEP), a selective mGluR5 negative allosteric modulator (NAM), 
could block, but not reverse, the ex vivo induction of thalamo-amygdala LTP (129, 139) and late-
LTP (122), a putative neurophysiological correlate of long term threat-based memory (98). In the 
intact animal, in vivo hippocampal LTP was also shown to be susceptible to 
intracerebroventricular MPEP administration (115). In addition to blockade of mGluR5, recent 
advances in the development of mGluR5 PAMs have enabled experiments examining the effect 
of selective potentiation of these receptors on synaptic plasticity in fear circuits. For example, ex 
vivo application of VU-29, a selective mGluR5 PAM, augmented subthreshold electrical 
induction of hippocampal LTP as well as stimulus or DHPG-induced hippocampal LTD (113). 
This finding was replicated with a novel mGluR5 PAM, ADX47273, and shown to be absent in 
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mGluR5 knockout mice (150), suggesting that mGluR5 participates in hippocampal-dependent 
contextualization of emotional memory. 
 mGluR5 activation has also been shown to be important for the acquisition of 
aversive learning in behaving animals. Multiple groups have demonstrated that systemic 
administration of MPEP blocks the acquisition of FPS (145, 151), cued CF (141), and CTA 
(144). It has also been found that infusion of MPEP directly into the amygdala is sufficient to 
inhibit the acquisition of cued and contextual CF (122, 139), and FPS (122), demonstrating that, 
along with mGluR1 and consistent with the electrophysiological evidence, the amygdala 
represents an important locus of action for Group I modulation of emotional memory acquisition. 
MTEP, an analogue of MPEP with similar pharmacological properties, also attenuated the 
acquisition of FPS (137), and contextual but not cued CF (127). More recently, it was shown that 
constitutive genetic deletion of mGluR5 in mice also impairs performance in contextual CF 
(149), although it is not possible in these animals to determine what specific phase of emotional 
memory formation or maintenance is compromised. The recent development of mGluR5-
selective PAMs has enabled studies examining the effect of mGluR5 activation on aversive 
associative conditioning. Consistent with previous studies demonstrating the importance of 
mGluR5 signaling in encoding threat-based memory, a recent study found that the novel mGluR5 
PAM VU0409551 enhances acquisition of contextual CF (223).  
In addition to its role in acquisition of emotional memory, there is an extensive literature 
demonstrating the importance of mGluR5 activation for the expression of aversive learning. It 
was first shown in 1997 that S-4C3H-PG, a non-selective Group I mGluR antagonist, increased 
punished responding in rodents (119), an effect considered to be anxiolytic. Systemic 
administration of the selective mGluR5 NAMs, MPEP or MTEP, also inhibited the expression of  
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Figure 4. mGluR5 and NMDA receptor involvement in synaptic correlates of emotional 
memory. Adapted from (224). mGluR5 canonically couples to the Gαq/11 subtype of G proteins; 
when activated by stress-induced glutamate release, mGluR5 ultimately leads to the induction of 
downstream effectors that mediate synaptic remodeling and memory formation/maintenance. 
Many of these downstream signaling molecules lie in the pathway that is activated by NMDA 
receptors, offering an indirect means of targeting the NMDA receptor for therapeutic purposes. 
This process is also dependent on new protein synthesis which allows for synaptic remodeling 
and long term memory storage that, in a subset of individuals leads to PTSD symptoms after 
trauma. 
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fear-based memory as measured by FPS (117, 145), cued or contextual CF (127), punished 
responding (114, 137, 140, 147), and aversive place conditioning (112). Similar to these 
prototypical compounds, the novel mGluR5-selective NAM, VU0285683, was shown to increase 
punished responding (140). Contrary results have been obtained in which there was no effect of 
MPEP on expression of FPS (122) or cued or contextual CF (122, 139); however, both of these 
experiments employed direct infusion of the compound into the amygdala, suggesting that the 
locus of action for mGluR5 antagonism on fear expression may include brain regions outside the 
amygdala.  
 
Sleep-dependent emotional memory  
One mechanism through which the activation or inhibition of mGluR5 and other mGluRs 
may mediate emotional memory encoding is by altering the amount, timing, or quality of sleep 
(34, 225, 226). In both rodents and humans, non-rapid eye-movement (NREM) and rapid eye-
movement (REM) sleep accrued after learning has been shown to promote the successful 
consolidation of new memory as evidenced by improved recall or performance on a given task 
after a delay (34, 225, 226). Mammalian sleep-wake architecture is highly conserved between 
species (227) such that rodents provide a valid translational model of normal human sleep 
patterns, as well as aberrant sleep related to various disease states (228, 229). Similar to human 
sleep studies, rodent sleep is measured using electroencephalography (EEG), in which electrodes 
are placed in contact with the scalp (in humans) or the dura mater (in rodents), allowing for the 
detection of electricity generated primarily by cortical neuronal ensembles (227, 228, 230). 
Based on characteristic changes in the oscillatory electrical activity in the brains of both species, 
it is possible to detect transitions between arousal states, from wake to NREM sleep to REM 
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sleep (227, 228, 230) (Figure 5). Although rodents are nocturnal, they cycle between 
wakefulness, through deepening stages of NREM sleep, and into bouts of REM sleep in the same 
stereotypical manner as humans (227, 228, 231). Both rodents and humans exhibit longer, more 
frequent bouts of NREM sleep early in the quiescent phase, transitioning to lighter NREM sleep 
and more frequent entries into REM sleep as the active phase approaches (227, 228, 231, 232). 
 Physiological pressure to enter NREM sleep is generated by the gradual accumulation of 
adenosine, a by-product of activity-dependent use of adenosine triphosphate (ATP) (227). 
Adenosine acts primarily through the adenosine receptor subtype 2A to activate γ-aminobutyric 
acid (GABA)-ergic neurons in the ventrolateral preoptic (VLPO) region of the hypothalamus 
which project to and inhibit wake-stabilizing orexinergic neurons in the lateral hypothalamus, 
histaminergic neurons in the tuberomammillary nucleus, serotonergic neurons in the dorsal 
raphe, and noradrenergic neurons in the locus coeruleus (227). During wake, orexinergic and 
monoaminergic neurons are active, and mediate reciprocal inhibition of the VLPO, ensuring that 
sleep is not initiated suddenly or unexpectedly (227). Once NREM sleep is initiated, periodic 
transition into REM sleep is caused by the activation of REM-on glutamatergic and cholinergic 
cells in the pontine reticular formation (PRF) and the laterodorsal/pedunculopontine tegmental 
nuclei (LDT/PPT), which project to the cortex and limbic regions of the brain, causing 
paradoxical excitation of the cortical EEG during REM sleep (227). Firing of monoaminergic 
neurons during REM sleep approaches zero, however, and the extracellular content of serotonin 
(5-HT), norepinephrine, and dopamine in the cortex, hippocampus and amygdala is very low, 
despite functional magnetic resonance imaging (fMRI) studies that reveal significant activation 
of these regions (227). The serotonergic system, in particular, is a key regulator of both sleep-
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wake architecture and emotional memory (233), and represents one of the neurochemical links 
between these two closely associated physiological and behavioral processes.  
While NREM sleep appears to confer a benefit primarily to the consolidation of 
declarative or episodic memory (34, 225, 226), REM sleep seems to be particularly important for 
the consolidation and contextualization of emotional memory (34, 225, 226, 234-239), although 
recent findings suggest involvement of NREM sleep in this process as well (238). The 
accumulation of REM sleep after emotional learning promotes the consolidation of memory 
related to the content of the new information as well as its emotional valence (226, 235, 237, 
240). This finding appears to be consistent regardless of the phase of emotional memory 
encoding; REM sleep can improve emotional memory consolidation after initial acquisition (226, 
236, 240), reconsolidation (34), or extinction (241-244) in both rodents and humans.  
The amount of time spent in each sleep state is not the only factor that determines its 
contribution to emotional memory formation and maintenance. The spectral composition of the 
EEG can also change within each sleep-wake state, and these changes are associated with 
different physiological and behavioral consequences. Although these transitions can be visually 
distinguished by qualitatively examining the EEG, quantitative EEG (qEEG) methods can also 
be applied to quantify the relative contribution of different frequencies to the total EEG 
waveform (Figure 5). These frequencies are grouped into the conventional power bands delta (δ: 
0.5-4 Hz), theta (θ: 5-8 Hz), alpha (α: 9-13 Hz), beta (β: 14-30 Hz), low gamma (low γ: 31-50 
Hz), and high gamma (high γ: 51-100 Hz). The prominence of each power band in the EEG 
changes depending on arousal state (227, 228, 230, 231). For example, waking EEG is 
characterized by power in mixed frequencies, NREM sleep by global increases in delta power, 
and REM sleep by increases in theta power (227, 228, 230, 231).  
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The power of each band is not discrete, but can fluctuate continuously within each sleep-
wake state (227, 228, 230, 231). Within-state alterations in the relative power of each band are 
associated with different behavioral outcomes (227, 228, 230, 231), and thus may be useful as 
biomarkers of disease and/or treatment (228). For example, the low frequency delta oscillations 
present during NREM sleep, also known as slow wave activity (SWA), are a well-established 
neurophysiological correlate of the r estorative properties of deep sleep (231, 232), and have 
been shown to be the component of NREM sleep most important for promoting the consolidation 
of declarative memory (225, 245). In multiple human studies with both healthy subjects and 
patients with mental illness associated with cognitive impairments, it has now been shown that 
this relationship is causative; when SWA is experimentally amplified, recall of prior learning is 
improved (245-249). For example, using transcranial induction of slow oscillations during 
NREM sleep, it was shown that declarative memories could be enhanced in healthy subjects 
(245). 
The memory-enhancing function of REM sleep is also dependent on the spectral 
composition of the EEG. In particular, increases in theta power during REM sleep have been 
correlated with enhanced emotional memory consolidation in humans and rats (240, 250, 251). 
Notably, increased REM sleep duration and theta power are not only associated with improved 
recall after learning, but this enhancement is strongest for negatively valenced information (239, 
240), suggesting that REM sleep preferentially promotes the consolidation of negative emotional 
memory. For example, after memorizing names associated with pictures of faces exhibiting 
neutral or negative expressions, REM sleep positively correlated with recall of the negative facial 
expressions, but not the neutral ones (240). 
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Figure 5. Representative rodent EEG and spectral power analysis characterizing each 
sleep-wake state. Characteristic changes in the EEG delineate transitions between each sleep-
wake state for both rodents and humans. These changes can be visually distinguished in order to 
stage sleep-wake architecture. qEEG methods can also be applied to decompose the total EEG 
waveform into its component frequency bands. When power in each band is plotted as a function 
of frequency, it is clear that the spectral composition of the EEG is distinct between each sleep-
wake state. This method also allows for the detection of changes in power spectra within each 
sleep-wake state that are associated with different behavioral outcomes.   
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Although these studies have primarily been performed in the experimental setting, it is likely that 
post-trauma accumulation of REM sleep similarly contributes to the consolidation of traumatic 
memory and may spur the development of PTSD symptoms (252). 
Thus, any pharmacological treatment aimed at therapeutically blocking emotional 
memory consolidation in the aftermath of traumatic stress should impinge on both wake and 
sleep-dependent memory encoding processes. As mentioned above, glutamate signaling in 
cortical and subcortical brain regions is a key mediator of emotional memory formation and 
maintenance during wakefulness, but it is also critical for the regulation of sleep-wake 
architecture and state-dependent qEEG spectral power (225). Selective antagonism or genetic 
deletion of different iGluRs and mGluRs has been found to differentially alter these measures 
with correlated behavioral consequences in both rodents and humans (253-278). For example, 
noncompetitive NMDA receptor antagonism with the rapid-acting antidepressant ketamine has 
been shown to specifically reduce REM sleep and enhance SWA, an effect that correlated with 
treatment response in depressed patients (263, 277, 278). Ketamine has also been found to 
increase gamma power in the frontal cortex during wake in rodents and humans, a measure that 
was successfully used as a translational biomarker of central target engagement (279). These 
studies highlight the importance of examining sleep-dependent effects of drug treatment, and 
underscore the potential value of employing qEEG as a biomarker of both target engagement and 
efficacy. NMDA receptor antagonist-induced suppression of REM sleep could also explain the 
effectiveness with which this class of compounds impairs emotional memory consolidation in 
rodents and humans. Although emotional memory consolidation is sensitive to both 
pharmacological treatment and sleep deprivation (226, 252, 280-282), it is important to note that 
there may be a critical temporal window for modifying this process (37). Indeed, depending on 
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the physiological or behavioral endpoint, NMDA receptor blockade and REM sleep deprivation 
lose the ability to attenuate memory consolidation if performed hours to days after emotional 
learning (37, 283, 284). Again, although preliminary evidence suggests that this window may be 
as short as six hours in victims of trauma (31, 37) most of these studies have been performed in 
experimental settings on healthy human participants, or on rodents subjected to mild aversive 
associative conditioning paradigms. Thus, it is not clear whether NMDA receptor antagonism 
after more severe traumatic stress can prevent traumatic memory consolidation and/or PTSD 
symptom progression, nor is it known exactly what role REM sleep may play in this process.  
Unfortunately, to date, no clinical study has objectively measured the effect of trauma on 
human sleep-wake architecture within hours to days of the traumatic experience (285). The 
earliest time point at which polysomnographic EEG has been collected in humans is between one 
week and two months after trauma (286-290). Furthermore, no sleep-dependent pharmacological 
or behavioral intervention has been attempted in victims of trauma until days after the event 
(291, 292), likely missing what may be the critical temporal window during which REM sleep 
suppression would be therapeutic (37, 283, 284). The logistical hurdles inherent to the collection 
of human EEG data at earlier time points highlight the importance of a valid rodent model of 
trauma-induced sleep-wake alterations. Such a model would enable studies in which 
pharmacological manipulation of sleep-wake architecture and state-dependent qEEG spectral 
power could be tested as a means of attenuating the development of PTSD-like symptoms after 
trauma. Given the impressive attenuating effect of NMDA receptor antagonism on both REM 
sleep and emotional memory consolidation, it would be of interest to test the effect of NMDA 
receptor blockade, and associated REM sleep suppression, on traumatic stress-induced 
physiological and behavioral alterations. However, as previously mentioned, translation of these 
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findings to the clinic would be impeded by the known adverse effects and formulation 
constraints associated with NMDA receptor antagonists such as ketamine (87, 88). 
Recently, it was found that the selective mGluR5 NAM 2-methyl-6-
(phenylethynyl)pyridine (MPEP) has similar effects to NMDA receptor antagonists, specifically 
suppressing REM sleep, enhancing SWA, and inducing increased gamma power during 
wakefulness in rodents (253, 258), possibly with fewer and/or less severe adverse effects (293). 
These findings are consistent with cellular data pointing to the structural and functional coupling 
of mGluR5 and NMDA receptors (99-101, 103, 106, 107, 294). They also suggest that both 
NMDA receptor and mGluR5 activation may promote emotional memory formation in part 
through increasing time spent in REM sleep after emotional learning. Indeed, antagonism of 
mGluR5, possibly through downstream inhibition of NDMA receptor function, has been shown 
to attenuate emotional memory acquisition, consolidation, and extinction at the neural and 
behavioral level in multiple rodent assays of threat learning (113, 115, 122, 129, 138, 139, 144, 
145, 149, 150). These observations suggest that mGluR5 NAMs could be used in a prophylactic 
approach to block the consolidation of emotional memory immediately after a traumatic event, 
possibly impeding the development of PTSD symptoms. Despite promising results in rodent 
behavioral assays of emotional memory (113, 115, 122, 129, 138, 139, 144, 145, 149, 150), 
however, mGluR5 NAMs have not been tested in a rodent model of traumatic stress such as SPS. 
 
Outline of current studies 
Thus, in Chapter 2, we performed studies intended to test whether SPS can be used as a 
rodent model of traumatic stress-induced physiological and behavioral alterations that would 
mimic PTSD patients. Specifically, we examined short and long-term alterations in sleep-wake 
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architecture and state-dependent qEEG spectral power. We also measured corresponding 
changes in several validated physiologic measures of the rodent stress response, as well as 
alterations in brain regional serotonergic signaling that may relate to observed disruptions in 
EEG measures. Then we determined whether these alterations have behavioral consequences, 
testing the effect of SPS on subsequent threat learning. 
Having validated the model, in Chapter 3, we attempted to pharmacologically intervene 
in the deleterious effects of SPS. First, we tested the effects of systemic administration of 3-
fluoro-N-(4-methylthiazol-2-yl)-5-(pyrimidin-5-yloxy)benzamide (VU0409106), a novel, 
selective, brain penetrant mGluR5 NAM (295) on rat sleep-wake architecture and state-
dependent qEEG spectral power to confirm that it behaves similar to reported mGluR5 NAMs in 
these measures. Then, we tested the effects of VU0409106 on multiple rodent assays of sedation 
and motor impairments to determine the therapeutic range of this compound, and to aid in 
selecting a dose for subsequent studies. Finally, we measured the effects of post-trauma 
administration of VU0409106 on SPS-induced alterations in behavior, sleep-wake architecture, 
qEEG spectral power, and brain regional serotonin (5-HT) utilization. We hypothesized that 
VU0409106, in part through acute suppression of REM sleep and impairment of emotional 
memory consolidation would attenuate the subsequent physiological and behavioral effects of 
SPS. 
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CHAPTER 2 
 
TRAUMATIC STRESS INDUCES LASTING SLEEP AND QUANTITATIVE 
ELECTROENCEPHALOGRAPHIC DISTURBANCES IN RATS 
 
Introduction 
SPS represents a valid model of traumatic stress that recapitulates many of the 
physiological and behavioral alterations present in PTSD patients (59). However, despite the 
prevalence, severity, and intractability of hyperarousal-associated sleep disturbances associated 
with PTSD (2, 11), it is not known whether SPS induces alterations in sleep-wake architecture 
and state-dependent qEEG power spectra similar to those seen in patients. 
Polysomnographic studies in chronic PTSD patients as well as recently traumatized 
individuals have revealed deficits in both NREM and REM sleep, including reduced and 
fragmented NREM and REM sleep, shortened latency to REM sleep, and increased REM density 
(2, 288-290, 296). Abnormalities in state-dependent qEEG power spectra indicative of 
heightened arousal during wakefulness, such as increased high frequency beta power, and 
inappropriate cortical activation during NREM sleep, such as reduced low frequency delta power 
(aka SWA) have also been observed in individuals with PTSD (297-301). These abnormalities 
are correlated with the previously discussed structural and functional alterations in the HPA axis, 
hippocampus, PFC, and amygdala (29). 
As mentioned, SSRIs are the front-line treatment for PTSD (10); this, combined with the 
finding that PTSD susceptibility and severity is associated with a 5-HT transporter gene 
polymorphism (302-305) implicates disrupted serotonergic neurotransmission in the 
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pathophysiology of the disorder. Recent studies suggest that SSRIs may partially exert their 
therapeutic effects through modulation of neuropeptide Y (NPY) and its Y1 and Y2 receptor 
subtypes (306). NPY has anxiolytic (307, 308) and sleep-promoting (309, 310) properties, and is 
significantly decreased in the plasma and cerebrospinal fluid (CSF) of PTSD patients (311, 312). 
Previous anatomical studies have shown that serotonergic terminals synapse onto NPY-
expressing inhibitory interneurons in the amygdala (313), suggesting the possibility that 
combined disruption of these neurotransmitter systems may contribute to hyperarousal symptoms 
and sleep-wake disruptions in PTSD patients.  
In order to test this hypothesis, and to determine whether SPS induces accompanying 
alterations in sleep-wake architecture and state-dependent qEEG power spectra, we 
telemetrically recorded EEG from rats in their home cage. Specifically, we tested whether SPS 
causes reduced and fragmented NREM and REM sleep that persists beyond the day of traumatic 
stress, similar to PTSD patients. In addition, we performed qEEG spectral power analysis to 
evaluate whether SPS induces markers of chronically increased cortical activation during wake 
and NREM sleep consistent with PTSD-like hyperarousal. To determine whether alterations in 
sleep-wake architecture coincided with activation of the HPA axis, we assessed changes in 
several validated physiologic measures of the rodent stress response including hyperthermia, 
increases in plasma corticosterone (314), and induction of FKBP5, an early stress-responsive 
gene that acts as a co-chaperone of the glucocorticoid receptor complex (66). Finally, we 
evaluated the effects of SPS on regional 5-HT utilization, and expression of NPY and its 
receptors to assess whether disruption of these neurotransmitter systems may be involved in 
mediating SPS-induced sleep-wake and qEEG spectral power alterations. 
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Methods 
 
Subjects 
All male Sprague-Dawley rats (Harlan, Indianapolis, IN) used in the present studies were 
housed under a 12 hour light:12 hour dark cycle and given ad libitum access to food and water. 
All animal experiments were approved by the Vanderbilt University Animal Care and Use 
Committee and experimental procedures conformed to guidelines established by the National 
Research Council Guide for the Care and Use of Laboratory Animals. All efforts were made to 
minimize animal suffering and the number of animals used. 
 
Surgery 
Twenty male rats (250-375 grams) were surgically implanted with a telemetry transmitter 
(4-ET, Data Sciences International, St. Paul, MN) for recording EEG, electromyography (EMG), 
and body temperature. Under isoflurane anesthesia (3% induction; 1.5-2.5% maintenance) the 
transmitter was implanted subcutaneously across the back of each rat. Transmitter leads were 
tunneled subcutaneously to the skull. After holes were drilled in the skull, the exposed wires 
were placed in contact with the dura and secured in place with dental cement (Butler Schein, 
Dublin, OH). Three sets of leads were placed bilaterally to record from cortical regions 
corresponding with the frontal, parietal, and occipital cortices (+2 mm, -2 mm, and -6mm 
anterior-posterior from Bregma, respectively and +/- 2 mm lateral to the midline). An additional 
set of leads was placed bilaterally in the nuchal muscles for EMG recording. Rats were 
individually housed following surgery and allowed to recover and acclimate to the recording 
room for a minimum of 10 days prior to testing.  
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Experimental design 
After post-operative recovery, each rat was randomized into either the SPS or SHAM 
group. Continuous 24 hour baseline (BL) recordings were performed for each rat in its home 
cage to serve as within-subjects comparator for all subsequent sleep-wake, qEEG, and body 
temperature data. After BL recordings, each rat received either SPS or SHAM treatment. 
Immediately following treatment, home cage recordings were re-initiated in both groups (Day 0), 
continued for two days (Days 1 and 2) after which transmitters were turned off, then reactivated 
on Day 7. Subsequent off-line analysis of sleep-wake and qEEG data was divided into the 
remaining hours of Day 0, or in 24hr intervals comprising Days 1, 2, and 7 post-SPS or SHAM 
treatment. Figure 6 depicts the experimental design for the EEG studies (Cohort 1) as well as the 
time points for tissue collections for the biochemistry and neurochemistry studies (Cohort 2). For 
all experiments, SPS or SHAM treatment occurred within the first 6 hours of the light phase. 
 
Single Prolonged Stress 
SPS was performed according to Liberzon et al. (315). Briefly, rats were restrained for 2 
hours, followed by forced swim for 15 minutes in 24 ⁰C water. Following a 15 minute recovery 
period, rats were exposed to diethyl ether vapor in a bell jar until anesthesia. The SPS model did 
not cause mortality. SPS did illicit hallmarks of the rodent stress response such as porphyrin 
staining of the eyes, and urination and defecation. There were no major individual differences 
observed in these parameters during each experiment, and no inclusion or exclusion criteria were 
applied prior to the start of EEG recordings or tissue collection. SHAM treatment consisted of 
placement in a novel procedure room for 2 hours followed by brief handling. All animals were 
placed into fresh cages after treatment.  
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Figure 6. Experimental design for EEG studies and tissue collection.  In cohort 1, continuous 
EEG, EMG, and temperature data were telemetrically recorded from chronically implanted rats 
throughout successive 24 hour light-dark cycles (ON: 6:00AM; OFF: 6:00PM) before (BL) and 
several days after (Days 0, 1, 2, and 7) either single prolonged stress (SPS) or SHAM treatment. 
Both treatments were performed within the first 6 hours of the light phase on Day 0 during which 
recording was not possible; EEG data from this day was re-initiated when each animal was 
returned to its home cage. In cohort 2, non-implanted aged-matched rats underwent either SPS or 
SHAM treatment. SPS rats were sacrificed either one hour (Day 0), one day (Day 1), or seven 
days (Day 7) later; SHAM rats were sacrificed seven days later. 
 
Tissue collection 
For all biochemical and neurochemical endpoints, a group of thirty-six non-implanted 
rats was randomly assigned to SHAM treatment or one of three SPS groups (Day 0, 1 or 7). Rats 
were briefly anesthetized with isoflurane, and sacrificed by decapitation either immediately (Day 
0), one day (Day 1), or seven days (Day 7) after SPS; SHAM rats were sacrificed immediately 
after SHAM treatment. Hippocampus, amygdala, and PFC were dissected, rapidly frozen on dry 
ice, and stored at −80 °C for tissue mRNA and neurochemistry experiments. Trunk blood was 
collected into heparin-lined tubes, and then centrifuged at 5,000 rpm for 9 minutes at 4 °C to 
obtain plasma. 
 
Plasma corticosterone 
Corticosterone, the rodent analogue of the human glucocorticoid cortisol, was measured 
using a double antibody radioimmunoassay (RIA) kit (MP Biomedicals, Orangeburg, NY). 
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Tissue neurochemistry 
Tissue concentrations of 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) 
were determined by HPLC-ECD as described previously (316).   
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Alterations in mRNA expression levels of NPY and its Y1 and Y2 receptor subtypes 
were measured using Aqueous Micro kits (Life Technologies, Grand Island, NY) for RNA 
extraction, NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) 
for RNA quantification, QuantiTect Reverse Transcription Kit (QIAGEN, Hilden, Germany) for 
complementary DNA transcription, CFX96 Real-Time PCR Detection System (Bio-Rad, 
Hercules, CA) using primers from TaqMan Gene Expression Assays (Life Technologies) for 
qRT-PCR of rat NPY (Rn01410145_m1), Y1 (Rn02769337_s1), and Y2 (Rn00576733_s1). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control; data are 
presented using the comparative cycle threshold (CT) method normalized to SHAM-treated rats. 
 
Sleep staging 
EEG, EMG, and temperature data were collected with Dataquest A.R.T. 4.3 software 
(DSI, Minneapolis, MN) using a continuous sampling method. Telemetric data were sampled at a 
rate of 500 Hz and transmitted via a receiver (RPC-2, DSI) placed below the cage of each rat. 
Each receiver was connected to a data exchange matrix (DSI) which transferred EEG, EMG, and 
temperature data to a computer for off-line analysis. Two trained observers used Neuroscore 3.0 
software to manually stage each 10 second epoch as wake, NREM, or REM sleep based on 
accepted characteristic EEG and EMG oscillatory patterns (317). All 10 second epochs were 
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summed into 60 minute bins. For the acute effects of SPS or SHAM treatment on Day 0, 60 
minute bins were group averaged to examine the amount of time spent in wake, NREM, or REM 
sleep. To assess the prolonged effects of SPS or SHAM treatment (Days 1, 2, and 7), 12 hour 
bins comprising either the light or dark phase of a given day were group averaged. 
 
qEEG spectral power analysis 
qEEG relative power spectra from frontal and parietal electrodes were computed for each 
rat and on each day of recording in 10 second epochs in 1Hz bins from 0.5 to 100 Hz using a 
Fast Fourier Transform with a Hamming window and overlap ratio of 0.5. Relative power within 
each 1 Hz increment was calculated as a percent of total power, then binned by stage (wake, 
NREM, or REM), and averaged across the 12 hour light or dark phase to yield the state-
dependent relative power spectrum for each rat. To calculate the percent change from BL the 
following formula was used: 
 
% change=100* (relative power (posttreatment day))/(relative power (BL) )-100 
 
where relative power (posttreatment day) is the relative power value of a frequency bin of a rat 
on Day 0, 1, 2 or 7, and relative power (BL) is the BL value of the same frequency bin for the 
same rat during the corresponding sleep-wake stage and light-dark phase. The % change values 
were then group averaged. The qEEG changes are discussed in terms of changes in power bands 
defined based on convention as delta (0.5-4 Hz), theta (5-8 Hz), alpha (9-13 Hz), beta (14-30 
Hz), low gamma (31-50 Hz), and high gamma (51-100 Hz) (227). Slow wave activity (SWA) 
was defined as relative delta power in the frontal cortex during NREM sleep; a time course of 
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SWA changes was calculated by normalizing SWA values for each rat, in 2 hour bins, to the 
same rat’s BL SWA value during the first 2 hours of the light phase. 
 
Statistical analysis 
For the acute effects of SPS or SHAM on sleep-wake architecture (Day 0) and the effect 
of SPS or SHAM on qEEG spectral power, a repeated measures two-way analysis of variance 
(ANOVA) was applied; if significant, a Bonferroni post hoc test was performed with 
significance defined as P < 0.05 for sleep-wake data and P < 0.01 for qEEG data. For the 
prolonged effects of SPS or SHAM (Days 1, 2, and 7), a repeated measures one-way ANOVA 
followed by a Dunnett’s post hoc test was used with significance defined as P < 0.05. Two-way 
ANOVA without repeated measures was used to analyze temperature and SWA changes due to 
the fact that certain rats did not enter NREM or REM states during various 2 hour epochs 
resulting in randomly missing values. If significant, Bonferroni post hoc tests were conducted 
with significance defined as P < 0.05. Day 0 sleep-wake, qEEG, and temperature data were 
analyzed separately from Days 1, 2, and 7 to distinguish between the acute and prolonged effects 
of SPS, which could differ due to the short-term rebound effects of sleep deprivation. One rat in 
the SPS group did not enter REM sleep during the light phase of Day 0 and was excluded from 
spectral and temperature analysis for this period. One rat in the SHAM group was excluded from 
spectral and temperature analysis on Day 7 due to transmitter failure. For qRT-PCR, tissue 
neurochemistry, and plasma corticosterone data, analysis was performed by one-way ANOVA 
followed by Dunnett’s post hoc test with significance defined as P < 0.05. 
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Results 
 
SPS induced acute and persistent PTSD-like alterations in sleep-wake architecture. 
SPS induced robust acute increases in percent time awake (Figure 7A) (time [F18,162 = 7.99, P 
< 0.0001], interaction [F18,162 = 12.65, P < 0.0001]) with concurrent reductions in time spent in 
NREM (Figure 7B) (time [F18,162 = 8.55, P < 0.0001], treatment [F1,9 = 5.35, P = 0.04], 
interaction [F18,162 = 13.84, P < 0.0001]), and REM sleep (Figure 7C) (time [F18,162 = 5.08, P 
< 0.0001], interaction [F18,162 = 12.18, P < 0.0001]) during the light (rodent quiescent) phase. 
The reductions in NREM and REM sleep during the light phase were followed by a rebound in 
these states during the dark (rodent active) phase. In contrast, SHAM treatment produced minor 
reductions in percent time awake relative to BL (Figure 7D)  (time [F18,162  = 33.98, P < 
0.0001], treatment [F1,9 = 51.75, P < 0.0001]), and increased time spent in NREM (Figure 7E) 
(time [F18,162  = 33.62, P < 0.0001], treatment [F1,9 = 40.15, P = 0.0001]), and REM sleep 
(Figure 7F) (time [F18,162  = 11.8, P < 0.0001], treatment [F1,9 = 42.3, P = 0.0001]). 
We then determined the time spent in wake, NREM, and REM sleep on Days 1, 2, and 7 
post-SPS or SHAM treatment to determine whether SPS-induced sleep-wake alterations 
persisted beyond the day of traumatic stress. Increased wake and decreased NREM and REM 
sleep during the light phase persisted for at least 2 days post-SPS, but normalized by Day 7 (See 
Table 2 for statistical analysis). On Day 2, SPS caused reductions in NREM bout length, and 
increases in NREM bout number, indicative of sleep fragmentation. SHAM treatment produced 
no sustained effect on sleep-wake architecture (Table 3).  
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Figure 7. SPS induced acute alterations in sleep-wake architecture the day of treatment. 
SPS (left panels, n = 10) increased (A) % time spent in wake, and suppressed (B) time in NREM, 
and (C) time in REM sleep during the light phase. Both NREM and REM sleep rebounded 
during the dark phase. SHAM treatment (right panels, n = 10) caused the opposite effect, 
moderately decreasing (D) % time spent in wake, and increasing (E) time in NREM, and (F) time 
in REM sleep during the light phase. Black bar indicates dark phase. Missing values occur while 
the rats were removed from the recording room for treatment. No significant differences detected 
between SPS BL and SHAM BL. Data are depicted as mean + SEM. Comparison between 
treatment and BL performed by repeated measures two-way ANOVA. * P < 0.05, ** P < 0.01, 
*** P < 0.001, **** P < 0.0001 in Bonferroni post hoc test compared to BL. 
 
 
SPS induced acute and sustained PTSD-like alterations in state-dependent qEEG power 
spectra in the frontal cortex. 
We next tested the hypothesis that SPS would disrupt the normal qEEG power spectra 
within each sleep-wake state in a manner similar to that exhibited by PTSD patients. On Day 0, 
SPS significantly altered qEEG power spectra in the frontal cortex during light phase wake, 
 40 
causing an increase in relative theta and high gamma power (black line, Figure 8A) (frequency 
[F100,900 = 5.91, P < 0.0001], interaction [F100,900 = 5.91, P < 0.0001]). In addition, SPS 
induced qEEG power spectra changes during dark phase wake, resulting in increased alpha, beta, 
and low gamma power, and decreased high gamma power (black line, Figure 8D) (frequency 
[F100,900 = 33, P < 0.0001], interaction [F100,900 = 33, P < 0.0001]). 
 
 
Table 2. SPS induced persistent disturbances in sleep-wake architecture. 
 Light Phase 
 SPS BL SPS Day 1 SPS Day 2 SPS Day 7 F P 
WAKE (min/hr) 15.6 ± 0.7 18.7 ± 0.6*** 17.8 ± 0.4* 16.2 ± 0.8 7.80 <.001 
NREM (min/hr) 37.2 ± 0.8 35.7 ± 0.5* 35.9 ± 0.5 36.9 ± 0.6 3.11 .043 
REM (min/hr) 7.1 ± 0.3 5.6 ± 0.4*** 6.1 ± 0.3* 6.9 ± 0.4 10.0 <.001 
WAKE bouts/hr 10.8 ± 0.7 11.4 ± 0.8 12.4 ± 0.7 10.9 ± 1.0 2.21 .110 
NREM bouts/hr 11.1 ± 0.7 11.8 ± 0.8 13.0 ± 0.6* 11.1 ± 1.0 3.63 .026 
REM bouts/hr 4.1 ± 0.2 3.4 ± 0.2 4.1 ± 0.2 4.0 ± 0.4 2.25 .106 
WAKE bout (min) 1.3 ± 0.1 1.6 ± 0.1* 1.4 ± 0.1 1.4 ± 0.1 2.88 .054 
NREM bout (min) 3.5 ± 0.3 3.1 ± 0.2 2.8 ± 0.2** 3.1 ± 0.2 5.43 .005 
REM bout (min) 1.8 ± 0.1 1.6 ± 0.1 1.5 ± 0.1 1.7 ± 0.1 2.62 .071 
 
Dark Phase 
 SPS BL SPS Day 1 SPS Day 2 SPS Day 7 F P 
WAKE (min/hr) 37.2 ± 1.0 30.6 ± 2.2*** 31.6 ± 1.4* 33.6 ± 1.7 7.09 .001 
NREM (min/hr) 19.9 ± 0.8 23.8 ± 1.8** 24.1 ± 1.2* 22.8 ± 1.5 6.27 .002 
REM (min/hr) 2.9 ± 0.3 5.5 ± 0.7*** 4.3 ± 0.3 3.6 ± 0.3 7.34 <.001 
WAKE bouts/hr 8.4 ± 0.3 8.8 ± 0.6 8.9 ± 0.9 8.6 ± 0.6 .257 .856 
NREM bouts/hr 8.4 ± 0.3 9.0 ± 0.6 9.1 ± 0.9 8.8 ± 0.6 .508 .680 
REM bouts/hr 2.5 ± 0.2 3.0 ± 0.2 2.8 ± 0.2 2.7 ± 0.3 1.14 .350 
WAKE bout (min) 4.3 ± 0.3 3.5 ± 0.3 4.1 ± 0.5 4.7 ± 0.7 1.86 .160 
NREM bout (min) 2.4 ± 0.1 2.8 ± 0.1 2.6 ± 0.2 2.5 ± 0.2 1.80 .172 
REM bout (min) 1.2 ± 0.1 1.5 ± 0.1*** 1.3 ± 0.0 1.2 ± 0.1 10.7 <.001 
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Table 3. SHAM treatment had no persistent effect on sleep-wake architecture. 
 Light Phase 
 SHAM BL SHAM Day 1 SHAM Day 2 SHAM Day 7 F P 
WAKE (min/hr) 16.8 ± 0.7  16.5 ± 0.7  16.3 ± 0.6  14.8 ± 0.8  2.59  .125  
NREM (min/hr) 35.6 ± 0.8  36.2 ± 0.6  36.7 ± 0.6  37.5 ± 0.8  1.76  .181  
REM (min/hr) 7.5 ± 0.3  7.4 ± 0.3  7.0 ± 0.3  7.6 ± 0.3  1.06  .385  
WAKE bouts/hr 12.8 ± 0.7  12.9 ± 0.7  12.8 ± 1.0  11.6 ± 1.1 1.51  .238  
NREM bouts/hr 13.5 ± 0.8 13.4 ± 0.6 13.2 ± 0.9 12.3 ± 0.9 1.39  .270  
REM bouts/hr 5.3 ± 0.3  5.0 ± 0.3 5.2 ± 0.4  5.5 ± 0.3 .914  .449  
WAKE bout (min) 1.3 ± 0.1  1.3 ± 0.1  1.3 ± 0.1 1.3 ± 0.1 .350  .790  
NREM bout (min) 2.8 ± 0.2  2.8 ± 0.2 2.9 ± 0.2 3.2 ± 0.3 2.60  .076  
REM bout (min) 1.5 ± 0.1  1.5 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 .603  .620  
 
Dark Phase 
 SHAM BL SHAM Day 1 SHAM Day 2 SHAM Day 7 F P 
WAKE (min/hr) 39.8 ± 0.9  37.5 ± 1.7  37.9 ± 1.4  37.7 ± 0.7  2.22  .111  
NREM (min/hr) 17.6 ± 0.9  19.5 ± 1.5  19.2 ± 1.3 19.69 ± 0.7  2.42  .091  
REM (min/hr) 2.6 ± 0.2  3.0 ± 0.3  2.9 ± 0.3  2.6 ± 0.2  1.29  .300  
WAKE bouts/hr 9.4 ± 0.4  11.2 ± 0.6  11.1 ± 0.5  10.8 ± 0.8  2.31  .102  
NREM bouts/hr 9.3 ± 0.4 11.2 ± 0.6 11.1 ± 0.5 10.9 ± 0.8  2.41  .092  
REM bouts/hr 2.6 ± 0.3 2.8 ± 0.3 2.8 ± 0.3  2.8 ± 0.2  .208  .890  
WAKE bout (min) 4.4 ± 0.3 3.5 ± 0.3  3.6 ± 0.3  3.7 ± 0.3  2.06  .132  
NREM bout (min) 1.9 ± 0.1 1.8 ± 0.1 1.7 ± 0.1 1.9 ± 0.1  .485  .696  
REM bout (min) 1.0 ± 0.0 1.1 ± 0.0 1.0 ± 0.0  1.0 ± 0.1  1.14  .353  
 
 
During light phase NREM sleep on Day 0, SPS increased delta and theta power, and 
decreased relative power in the higher frequencies (black line, Figure 8B) (frequency [F100,900 
= 9.31, P < 0.0001], treatment [F1,9 = 11.82, P = 0.0074], interaction [F100,900 = 9.31, P < 
0.0001]), while during dark phase NREM sleep, SPS caused a selective reduction in high gamma 
(black line, Figure 8E) (frequency [F100,900 = 4.90, P < 0.0001], treatment [F1,9 = 7.61, P = 
0.0222], interaction [F100,900 = 4.90, P < 0.0001]). Finally, during light phase REM sleep, SPS 
increased theta and alpha power on Day 0 (black line, Figure 7C) (frequency [F100,800 = 3.11, P 
 42 
< 0.0001], interaction [F100,800 = 3.11, P < 0.0001]), but decreased beta power during the dark 
phase (black line, Figure 8F) (frequency [F100,900 = 2.52, P < 0.0001], interaction [F100,900 = 
2.52, P < 0.0001]). 
These alterations in qEEG power spectra were sustained for multiple days after SPS. SPS 
increased beta and low gamma power, and decreased high gamma power during light phase 
wake (colored lines, Figure 8A) (frequency [F100,900 = 4.56, P < 0.0001], interaction 
[F300,2700 = 3.81, P < 0.0001]), and dark phase wake (colored lines, Figure 8D) (frequency 
[F100,900 = 17.96, P < 0.0001], interaction [F300,2700 = 10.32, P < 0.0001]) over the entire 7 
day time course. Delta power was significantly reduced for at least two days post-SPS during 
light phase NREM sleep, (colored lines, Figure 8B) (frequency [F100,900 = 5.02, P < 0.0001], 
treatment [F3,27 = 9.07, P = 0.0003], interaction [F300,2700 = 5.46, P < 0.0001]), and more 
moderately during dark phase NREM sleep (colored lines, Figure 8E) (frequency [F100,900 = 
6.05, P < 0.0001], treatment [F3,27 = 3.34, P = 0.0341], interaction [F300,2700 = 4.44, P < 
0.0001]). Most alterations in qEEG power spectra during REM sleep normalized by Day 2 with 
the exception of  a sustained decrease in delta during the light phase (colored lines, Figure 8C) 
(interaction [F300,2700 = 2.16, P < 0.0001]), and dark phase (colored lines, Figure 8F) 
(interaction [F300,2700 = 1.15, P = 0.0465]).  
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Figure 8. SPS induced acute and sustained alterations in qEEG power spectra in the 
frontal cortex. In the light phase (top panels), SPS caused (A) a transient increase in high 
gamma, and a prolonged increase in low gamma during wake; (B) an acute rebound, but a 
persistent subsequent reduction in delta power during NREM sleep; and (C) a prolonged 
decrease in delta power during REM sleep. In the dark phase (bottom panels), SPS caused (D) an 
increase in theta, alpha, and low gamma with a sustained increase in beta, and a sustained 
decrease in high gamma during wake; (E) a prolonged reduction in high gamma during NREM 
sleep; and (F) an acute increase in theta during REM sleep. Day 0 only includes values from 
remaining hours of the light phase immediately after SPS treatment. Data are depicted as mean + 
SEM (n = 9-10). Background shades delineate power bands delta (δ), theta (θ), alpha (α), beta 
(β), low and high gamma (γ). Comparison between treatment and BL performed by repeated 
measures two-way ANOVA. Colored lines below data points correspond to each day and 
indicate P < 0.01 in Bonferroni post hoc test. 
 
 
SPS induced acute and sustained PTSD-like alterations in state-dependent qEEG power 
spectra in the parietal cortex. 
SPS significantly disrupted the normal qEEG power spectra in the parietal cortex in a 
manner similar to that observed in the frontal cortex with a few notable differences. On Day 0, 
SPS significantly altered qEEG power spectra in the parietal cortex during light phase wake 
(black line, Figure 9A) (frequency [F100,900 = 12.19, P < 0.0001], treatment [F1,9 = 37.86, P < 
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0.0001] interaction [F100,900 = 12.19, P < 0.0001]) and dark phase wake (black line, Figure 9D) 
(frequency [F100,900 = 6.7, P < 0.0001], interaction [F100,900 = 6.7, P < 0.0001]) but did not 
cause reduced high gamma power as in the frontal cortex. During light phase NREM sleep, SPS 
caused a short-term rebound in delta power (black line, Figure 9B) (frequency [F100,900 = 7.69, 
P < 0.0001], treatment [F1,9 = 8.99, P = 0.0150], interaction [F100,900 = 7.69, P < 0.0001]), but 
had no effect during dark phase NREM sleep (black line, Figure 9E). Unlike in the frontal 
cortex, SPS caused a significant increase in alpha and low beta power during light phase REM 
sleep, (black line, Figure 9C) (frequency [F100,800 = 3.61, P < 0.0001], interaction [F100,800 = 
3.61, P < 0.0001]), and dark phase REM sleep(black line, Figure 9F) (frequency [F100,900 = 
8.09, P < 0.0001], interaction [F100,900 = 8.09, P < 0.0001]), but had little or no effect on theta. 
Similar to the frontal cortex, SPS-induced qEEG changes were largely sustained in the parietal 
cortex during light phase wake (colored lines, Figure 9A) (frequency [F100,900 = 4.0, P < 
0.0001], treatment [F3,27 = 9.17, P = 0.0002], interaction [F300,2700 = 5.59, P < 0.0001]) and 
dark phase wake (colored lines, Figure 9D) (frequency [F100,900 = 4.48, P < 0.0001], 
interaction [F300,2700 = 2.52, P < 0.0001]); light phase NREM, (colored lines, Figure 9B) 
(frequency [F100,900 = 5.65, P < 0.0001], treatment [F3,27 = 4.65, P = 0.0095], interaction 
[F300,2700 = 3.88, P < 0.0001]); and light phase REM (colored lines, Figure 9C) (frequency 
[F100,900 = 1.47, P = 0.0028], interaction [F300,2700 = 1.89, P < 0.0001]), and dark phase 
REM sleep (colored lines, Figure 9F) (interaction [F300,2700 = 2.13, P < 0.0001]). 
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Figure 9. SPS induced acute and sustained alterations in qEEG power spectra in the 
parietal cortex. In the light phase (top panels), SPS caused (A) a transient increase in high 
gamma; (B) an acute rebound, but a persistent subsequent reduction in delta power during 
NREM sleep; and (C) an acute increase in alpha, and a prolonged decrease in delta power during 
REM sleep. In the dark phase (bottom panels), SPS caused (D) a transient increase in theta, 
alpha, and low gamma with a sustained increase in beta during wake; (E) no change during 
NREM sleep; and (F) an acute increase in alpha during REM sleep. Day 0 only includes values 
from remaining hours of the light phase immediately after SPS treatment. Data are depicted as 
mean + SEM (n = 9-10). Background shades delineate power bands delta (δ), theta (θ), alpha (α), 
beta (β), low and high gamma (γ). Comparison between treatment and BL performed by repeated 
measures two-way ANOVA. Colored lines below data points correspond to each day and 
indicate P < 0.01 in Bonferroni post hoc test. 
 
SHAM treatment had minor effects on state-dependent qEEG power spectra in the frontal 
and parietal cortices. 
In contrast to the robust and sustained effects of SPS, SHAM treatment had only minor 
effects on qEEG relative spectral power in the frontal cortex on Day 0 during light phase wake 
(Figure 10A) (frequency [F100,900 = 4.95, P < 0.0001], treatment [F1,9 = 5.8, P = 0.04], 
interaction [F100,900 = 4.95, P < 0.0001]), dark phase wake (Figure 10D) (frequency [F100,900 
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= 2.57, P < 0.0001], interaction [F100,900 = 2.57, P < 0.0001]), light phase NREM (Figure 10B) 
(frequency [F100,900 = 8.41, P < 0.0001], treatment [F1,9 = 8.14, P = 0.0190], interaction 
[F100,900 = 8.41, P < 0.0001]), dark phase NREM (Figure 10E) (frequency [F100,900 = 2.28, P 
< 0.0001], interaction [F100,900 = 2.28, P < 0.0001]), light phase REM (Figure 10C) (frequency 
[F100,900 = 1.37, P = 0.0134], interaction [F100,900 = 1.37, P = 0.0134]), and dark phase REM 
sleep (Figure 10F) (frequency [F100,900 = 1.36, P = 0.0139], interaction [F100,900 = 1.36, P = 
0.0139]).  
On Days 1, 2, and 7, SHAM treatment modestly altered power spectra during light phase 
wake (Figure 10A) (frequency [F100,800 = 3.34, P < 0.0001], interaction [F300,2400 = 1.51, P 
< 0.0001]), dark phase wake (Figure 10D) (frequency [F100,800 = 2.73, P < 0.0001], interaction 
[F300,2400 = 1.85, P < 0.0001]), light phase NREM (Figure 10B) (interaction [F300,2400 = 
1.48, P < 0.0001]), dark phase NREM (Figure 10E) (frequency [F100,800 = 3.81, P < 0.0001], 
interaction [F300,2400 = 1.36, P = 0.0001]), light phase REM (Figure 10C) (frequency 
[F100,800 = 2.00, P < 0.0001], interaction [F300,2400 = 2.42, P = 0.0001]), and dark phase 
REM sleep (Figure 10F) (frequency [F100,800 = 3.48, P < 0.0001], interaction [F300,2400 = 
1.98, P = 0.0001]). 
In the parietal cortex on Day 0, SHAM treatment modestly altered power spectra during 
light phase wake (Figure 11A) (frequency [F100,900 = 11.79, P < 0.0001], treatment [F1,9 = 
16.38, P = 0.0029], interaction [F100,900 = 11.79, P < 0.0001]), dark phase wake (Figure 11D) 
(frequency [F100,900 = 6.28, P < 0.0001], treatment [F1,9 = 10.33, P = 0.0106], interaction 
[F100,900 = 6.28, P < 0.0001]), light phase NREM (Figure 11B) (frequency [F100,900 = 4.74, P 
< 0.0001], treatment [F1,9 = 14.54, P = 0.0041], interaction [F100,900 = 4.74, P < 0.0001]), dark 
phase NREM (Figure 11E) (frequency [F100,900 = 2.14, P < 0.0001], interaction [F100,900 =  
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Figure 10. SHAM treatment had minor effects on qEEG power spectra in the frontal 
cortex. In the light phase (top panels), SHAM treatment had only minor effects during light 
phase (A) wake, (B) NREM, and (C) REM sleep, and during dark phase (D) wake, (E) NREM, 
and (F) REM sleep. Day 0 only includes values from remaining hours of the light phase 
immediately after SHAM treatment. Data are depicted as mean + SEM (n = 9-10). Background 
shades delineate power bands delta (δ), theta (θ), alpha (α), beta (β), low and high gamma (γ). 
Comparison between treatment and BL performed by repeated measures two-way ANOVA. 
Colored lines below data points correspond to each day and indicate P < 0.01 in Bonferroni post 
hoc test. 
 
 
2.14, P < 0.0001]), and dark phase REM sleep (Figure 11F) (frequency [F100,900 = 1.38, P = 
0.0107], treatment [F1,9 = 5.19, P = 0.0488], interaction [F100,900 = 1.38, P = 0.0107]). 
On Days 1, 2, and 7, SHAM treatment modestly altered power spectra in the parietal 
cortex during light phase wake (Figure 11A) (frequency [F100,800 = 3.42, P < 0.0001], 
interaction [F300,2400 = 1.50, P < 0.0001]), dark phase wake (Figure 11D) (frequency 
[F100,800 = 4.20, P < 0.0001], interaction [F300,2400 = 1.66, P < 0.0001]), light phase NREM 
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(Figure 11B) (interaction [F300,2400 = 1.51, P < 0.0001]), and dark phase REM sleep (Figure 
11F) (frequency [F100,800 = 1.45, P = 0.0044], interaction [F300,2400 = 1.30, P = 0.0010]). 
 
 
Figure 11. SHAM treatment had minor effects on qEEG power spectra in the parietal 
cortex. In the light phase (top panels), SHAM treatment had only minor effects during light 
phase (A) wake, (B) NREM, and (C) REM sleep, and during dark phase (D) wake, (E) NREM, 
and (F) REM sleep. Day 0 only includes values from remaining hours of the light phase 
immediately after SHAM treatment. Data are depicted as mean + SEM (n = 9-10). Background 
shades delineate power bands delta (δ), theta (θ), alpha (α), beta (β), low and high gamma (γ). 
Comparison between treatment and BL performed by repeated measures two-way ANOVA. 
Colored lines below data points correspond to each day and indicate P < 0.01 in Bonferroni post 
hoc test. 
 
 
SPS induced prolonged reductions in SWA 
SWA was highest during the early hours of the light phase, and gradually reduced across 
the quiescent period (Figure 12A), consistent with dissipation of sleep drive (232). Relative to 
BL, SPS increased SWA on Day 0 (treatment [F1,50 = 42.74, P < 0.0001]) consistent with the 
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rebound effects of sleep deprivation (232), but produced significantly decreased SWA on Days 1 
and 2 post-SPS treatment (Figure 12A) (time [F15,215 = 24.33, P < 0.0001], treatment [F15,215 
= 14.19, P < 0.0001]), especially during the early hours of the light phase. By contrast, relative to 
BL, SHAM increased SWA on Day 0 (time [F2,54 = 32.03, P < 0.0001], interaction [F2,54 = 
5.68, P = 0.0058], treatment [F1,54 = 42.23, P < 0.0001]) consistent with the rebound effects of 
sleep deprivation (232), but produced no prolonged effect on SWA (Figure 12B). No SWA 
differences were detected between SPS BL and SHAM BL. 
 
SPS induced an acute and persistent physiological stress response. 
Given the magnitude and duration of SPS-induced sleep-wake and qEEG disruptions, we 
measured concomitant changes in several validated measures of the rodent stress response, 
including hyperthermia, corticosterone release, and brain regional FKBP5 induction (66, 314). 
SPS induced acute and persistent hyperthermia for several days post-SPS (Figure 13A) during 
wake (Day 0: hour [F8,158 = 3.2, P = 0.0022], hour [F8,158 = 3.2, P = 0.0022]; Days 1,2,7: 
interaction [F33,430 = 1.69, P = 0.0116], treatment [F3,430 = 4.67, P < 0.0032], hour [F11,430 = 
5.29, P < 0.0001]), NREM (Day 0: hour [F8,155 = 2.13, P = 0.0357], treatment [F1,155 = 4.11, P 
< 0.0443], interaction [F8,155 = 2.13, P = 0.0357]; Days 1,2,7: interaction [F33,424 = 1.85, P = 
0.0035], treatment [F3,424 = 6.5, P < 0.0003], hour [F11,424 = 5.78, P < 0.0001]), and REM  
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Figure 12. SPS induced prolonged reductions in slow wave activity (SWA). (A) During the 
light (rodent quiescent) phase, SPS caused an initial rebound in SWA immediately after SPS, but 
subsequently reduced SWA for up to two days post-SPS. Data are depicted as mean - SEM (n = 
9-10). ^^^ P < 0.001, ^^^^ P < 0.0001, Day 0 vs. BL; * P < 0.05, ** P < 0.01, Day 1 vs. BL; # P 
< 0.05, #### P < 0.0001, Day 2 vs. BL in Bonferroni post hoc test. (B) SHAM treatment had no 
prolonged effect on SWA. During the light (rodent quiescent) phase, SHAM treatment caused an 
initial rebound in slow wave activity (SWA), but subsequently had no effect. Data are depicted 
as mean + SEM (n = 9-10). ^^ P < 0.01, ^^^^ P < 0.0001, Day 0 vs. BL in Bonferroni post hoc 
test. 
 
 
sleep (Day 0: hour [F8,118 = 2.84, P = 0.0064], treatment [F1,118 = 16.82, P < 0.0001], 
interaction [F8,118 = 2.84, P = 0.0064]; Days 1,2,7: interaction [F33,398 = 1.56, P = 0.0279], 
treatment [F3,398 = 5.91, P < 0.0006], hour [F11,398 = 6.63, P < 0.0001]), specifically during 
the light phase. In contrast to SPS, SHAM treatment had only minor effects on body temperature 
(Figure 13B) during wake (Day 0: hour [F8,162 = 4.07, P = 0.0002], treatment [F1,162 = 23.24, 
P < 0.0001], interaction [F8,162 = 4.07, P = 0.0002]; Days 1,2,7: hour [F11,418 = 4.2, P < 
0.0001], treatment [F3,418 = 4.35, P = 0.005]), NREM (Day 0: hour [F8,162 = 3.42, P = 
0.0012], treatment [F1,162 = 15.79, P = 0.0001], interaction [F8,162 = 3.42, P = 0.0012]; Days 
1,2,7: hour [F11,420 = 4.00, P < 0.0001], treatment [F3,420 = 4.13, P = 0.0066]), and REM 
sleep (Days 1,2,7: hour [F11,385 = 2.37, P = 0.0077]). 
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In parallel with body temperature increases, SPS rats exhibited robust acute HPA axis 
activation as evidenced by elevated plasma corticosterone (Figure 14A) [F3,29 = 14.67, P < 
0.0001]. In addition, there was a concurrent acute induction of FKBP5 mRNA levels in the brain 
regions that comprise the neural fear circuitry (Figure 14B) including the hippocampus [F3,28 = 
40.84, P < 0.0001], PFC [F3,28 = 25.43, P < 0.0001], and amygdala [F3,27 = 36.46, P < 0.0001]. 
 
 
 
Figure 13. SPS induced acute and persistent hyperthermia. SPS caused (A) increases in body 
temperature during the light phase of all sleep-wake states that lasted until Day 2. Black bars 
indicate dark phases. SHAM treatment (B) moderately reduced temperature relative to BL at 
various time points after treatment. Data are depicted as mean + SEM (n = 9-10). Comparison 
between treatment and BL performed by two-way ANOVA. * P < 0.05 in Bonferroni post hoc 
test.  
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SPS caused acute and sustained alterations in brain regional 5-HT utilization. 
Due to the well-established role of 5-HT in modulating anxiety and sleep-wake 
architecture (233), we tested whether the observed SPS-induced sleep-wake and qEEG power 
spectra changes were associated with altered 5-HT signaling. SPS produced acute increases in 
the levels of the 5-HT metabolite, 5-HIAA, in the PFC (Figure 14A) [F3,32 = 29.31, P < 0.0001] 
and hippocampus (Figure 15B) [F3,32 = 8.70, P = 0.0002], and prolonged reductions in the 
amygdala (Figure 15C) [F3,32 = 5.98, P = 0.0023] with no effect on 5-HT levels across the three 
brain regions (Figure 15D-F). 
 
SPS caused delayed reductions in amygdala expression of NPY. 
As previously discussed, NPY signaling in the amygdala plays a critical role in 
modulating the stress response (307); thus, we hypothesized that SPS would alter expression of 
NPY and its Y1 and Y2 receptor subtypes specifically in the amygdala. SPS caused NPY mRNA 
levels to be significantly reduced in the amygdala by Day 7 post-SPS (Figure 16A) [F3,26 = 
4.94, P = 0.0076], but had no effect on Y1 or Y2 mRNA levels (Figures 16B,C). 
 
Results summary 
SPS produced robust alterations in sleep-wake architecture accompanied by state-
dependent changes in qEEG power spectra that resemble PTSD symptomatology. These changes 
corresponded with time-dependent and brain region-specific alterations in physiological markers 
of HPA axis activation, 5-HT utilization, and NPY expression, suggesting key alterations in the 
neural fear circuitry that may potentially underlie PTSD-related hyperarousal and sleep-wake 
disturbances. 
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Figure 14. SPS induced an acute and persistent physiological stress response. SPS acutely 
increased plasma corticosterone concentrations (A), and FKBP5 mRNA levels in the 
hippocampus (B), PFC (C), and amygdala (D). Data are depicted as mean + SEM (n = 8-9). 
Comparison between SHAM and SPS Day performed by one-way ANOVA. * P < 0.05, *** P < 
0.001, **** P < 0.0001 in Dunnett’s post hoc test compared to SHAM. 
 
 
Discussion 
Our current findings demonstrate SPS-induced dysregulation and fragmentation of 
NREM and REM sleep that mirror the abnormal sleep-wake patterns of recently traumatized 
individuals (287, 288) and patients with chronic PTSD (296).   The observed changes in sleep-
wake architecture on Day 0 post-SPS likely represent the immediate effects of traumatic stress,  
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Figure 15. SPS caused acute and sustained alterations in brain regional 5-HT utilization. 
Concentration of the 5-HT metabolite 5-HIAA was increased by SPS on Day 0 in (A) the PFC 
and (B) the hippocampus, but decreased on Days 1 and 7 in (C) the amygdala. (D-F) 5-HT levels 
in these regions were not significantly affected. Data are depicted as mean + SEM (n = 8-9). 
Comparison between SHAM and SPS Day performed by one-way ANOVA. *P < 0.05, ** P < 
0.01 in post-hoc Dunnett’s test versus SHAM. 
 
 
which have not yet been objectively assessed in traumatized clinical populations. As mentioned 
above, the amount of NREM and especially REM sleep accumulated in healthy subjects 
immediately following emotional learning imparts strong and lasting benefits to the 
consolidation and subsequent recall of these memories (235, 236, 240), suggesting that acute 
SPS-induced reductions in sleep may actually represent a protective response in the hours after 
traumatic stress on Day 0.  In contrast, the significant fragmentation of NREM sleep coupled 
with increased wake time during the quiescent phases observed on Days 1 and 2 closely 
resemble documented sleep disruptions in chronic PTSD patients (2, 287, 288, 296, 318).  These 
insomnia-like reductions in NREM and REM sleep on Days 1 and 2, therefore, may be  
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Figure 16. SPS caused acute and sustained alterations in amygdala expression of 
neuropeptide Y (NPY). mRNA levels of NPY were reduced on Day 7 after SPS, while NPY 
receptor mRNA levels were not significantly altered in the amygdala. Data are depicted as mean 
+ SEM (n = 8-9). Comparison between SHAM and SPS Day performed by one-way ANOVA. 
** P < 0.01 in post-hoc Dunnett’s test versus SHAM. 
 
representative of the sleep symptoms present in patients with established disease, and are 
unlikely to be part of an early adaptive response to trauma.  
The SPS-induced alterations in qEEG power spectra during wake, NREM and REM sleep 
also recapitulate many of the qEEG abnormalities reported in PTSD patients. Augmentation of 
beta/low gamma power during wake in the active phase was one of the most enduring effects of 
SPS, lasting for at least 7 days. In chronic PTSD patient populations, increased waking beta/low 
gamma power has been reported both at rest (297, 299), and in response to affective stimuli 
(298), although this finding was absent in one study (319). Reductions in waking high gamma 
power were also sustained for 7 days post-SPS, a change that was specific to frontal cortical 
regions as it was absent in recordings from the parietal cortex. A recent fMRI study 
demonstrated that increases in high gamma power are correlated with activation of 
corresponding cortical regions (320). The current finding of SPS-induced reductions in this 
power band specifically in the frontal cortex, therefore, could be indicative of PFC hypoactivity, 
a commonly reported finding in PTSD patients (29). 
 56 
During NREM sleep, SPS caused a prolonged, but not acute, increase in beta/gamma 
power, and a decrease in SWA that mirrors similar deficits in patients with PTSD (300, 301), and 
likely indicates poor sleep quality (321). Interestingly, despite causing reduced SWA on Days 1 
and 2, SPS acutely caused a large increase in SWA on Day 0, again suggesting that rats may 
exhibit failed protective responses immediately after SPS, prior to the development of PTSD-like 
symptoms days later. This finding further supports the interpretation that the previously 
discussed sleep-wake architecture changes present on Days 1 and 2 represent sleep disturbances 
related to established PTSD. Impaired SWA has also been associated with impairments in sleep-
dependent fear extinction memory, a robust PTSD-like behavioral effect of SPS (59). 
Pharmacologically augmenting SWA, therefore, could represent a therapeutic approach for 
PTSD patients or recently traumatized individuals that can be tested in this model. In the case of 
REM sleep, the most significant change in frontal cortical qEEG spectral power was an acute 
increase in frontal theta power which is thought to promote emotional memory consolidation in 
rodents (250) and humans (240), perhaps contributing to the subsequent development of PTSD-
like symptoms in the SPS model. Future experiments correlating SPS-induced alterations in theta 
power during REM sleep with subsequent anxiety-like behaviors will be critical for 
understanding the function of these state-specific oscillations in the processing of traumatic 
events. 
In addition to causing sustained qEEG deficits indicative of hyperarousal, we confirmed 
that SPS concomitantly and robustly induces markers of HPA axis activation. For example, SPS 
induced hyperthermia during all sleep-wake states, and caused substantial increases in plasma 
corticosterone, consistent with previous findings (322). Corticosterone release was accompanied 
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by induction of FKBP5 expression, a gene that has been associated with PTSD risk, diagnosis, 
and treatment (67-69), and which may contribute to acute SPS-induced sleep loss (323).  
SPS-induced reductions in NREM and REM sleep during the quiescent phase could also 
be explained by acute increases in 5-HT utilization in the PFC and hippocampus, brain structures 
implicated in the modulation of sleep-wake architecture (3). This hypothesis is supported by 
reports that other acute stressors cause 5-HT release in multiple brain regions including the 
cortex, leading to inhibition of sleep (324). In the amygdala, however, SPS did not increase 5-HT 
utilization, but rather induced a delayed decrease on Days 1 and 7 which correlated with 
sustained increases in relative beta/low gamma power during wake. 5-HT exerts a net inhibitory 
influence on the excitability of lateral amygdala neurons (325, 326) which, when directly 
stimulated, can induce high frequency EEG oscillations (327) highly comparable to the long-
lasting effects of SPS. This finding may help to explain the partial efficacy of SSRIs on 
hyperarousal symptoms in PTSD patients and their behavioral correlates in SPS-treated rats (82, 
328). Similar to 5-HT, SPS caused a delayed reduction in expression of amygdala NPY which 
also acts to inhibit the firing of projection neurons in the lateral amygdala (329). Importantly, 
this finding is consistent with previous studies demonstrating the therapeutic efficacy of 
exogenous NPY administration in SPS-treated rats (330, 331). Moreover, intracerebroventricular 
infusion of NPY in rats increases low frequency and decreases beta frequency qEEG spectral 
power (332, 333), in direct opposition to the long-term effects of SPS. The changes in NPY 
expression reported here were at the level of mRNA, however, and may not translate into 
reductions in amygdala peptide concentration, or more importantly, peptide release. 
Collectively, we have demonstrated that SPS, a rodent model of traumatic stress, leads to 
alterations in sleep-wake architecture and state-dependent qEEG spectral power that correlate 
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with regional changes in 5-HT utilization and NPY expression, providing new understanding of 
possible mechanisms underlying the pathophysiology of PTSD-related hyperarousal and sleep 
disturbances. Taken together, the observed alterations in sleep-wake architecture also offer novel 
insight into the acute effects of trauma while simultaneously recapitulating longer term PTSD 
symptoms, thereby providing an attractive model for testing the efficacy of sleep-dependent 
prophylactic interventions in the aftermath of a traumatic event. 
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CHAPTER 3 
 
SELECTIVE ANTAGONISM OF mGluR5 MODULATES SLEEP-WAKE 
ARCHITECTURE AND AMELIORATES BEHAVIORAL ABNORMALITIES 
INDUCED BY TRAUMATIC STRESS IN RATS 
 
Introduction 
 The proximal cause of PTSD is the acquisition and consolidation of a traumatic memory, 
suggesting that modulation of traumatic memory formation or maintenance may be a viable 
approach to the prevention or treatment of PTSD symptoms (14, 16, 18, 20). Pharmacological 
manipulation of glutamatergic signaling before, during, or after trauma offers a promising target 
for this strategy. Glutamate-mediated activation of NMDA receptors, and ensuing induction of 
synaptic plasticity in the hippocampus, PFC, and amygdala, is required for the successful 
acquisition and consolidation of threat-based memories (33, 35). These preclinical findings 
suggest that systemic NMDA receptor antagonism in the aftermath of trauma could impede the 
development of PTSD symptoms.  
As mentioned above, NMDA receptor activation may promote consolidation of fear-
based memory in part through the induction of REM sleep (34, 225, 226, 234-239). NMDA 
receptor antagonists reduce REM sleep in rats (256, 257, 264, 268) and humans (263, 277, 278), 
possibly contributing to their blockade of emotional memory consolidation. Unfortunately, the 
adverse effects associated with currently available NMDA receptor antagonists including 
drowsiness, hallucinations, and abuse potential limit their clinical utility (87, 88). An alternative 
strategy to direct blockade of NMDA receptors is to inhibit NMDA receptor-mediated signaling 
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through antagonism of mGluR5, which is structurally and functionally coupled to NMDA 
receptors in the hippocampus, PFC, and amygdala (99-101, 103, 106, 107, 294). mGluR5 
antagonism with the prototypical mGluR5 NAM MPEP has been shown to attenuate NMDA 
receptor-mediated signaling and to induce similar physiological and behavioral effects of NMDA 
receptor antagonists but with fewer adverse effects (101, 334, 335). Importantly, MPEP and 
other mGluR5 antagonists potently reduce REM sleep similar to NMDA receptor blockers (253, 
258).  
Recently, our group reported the discovery of VU0409106, a novel, potent and selective 
mGluR5 NAM with favorable pharmacokinetic properties for in vivo testing (223, 295, 336). In 
vitro evaluation of VU0409106 has revealed that this compound competitively binds at the 
allosteric MPEP binding site, completely attenuates glutamate-mediated calcium mobilization 
(IC50 = 24nM) in HEK293A cells heterologously expressing mGluR5, and displays no significant 
off-target activity at any of the other seven mGluRs (295). Importantly, positron emission 
tomography (PET) imaging in rats has revealed that VU0409106 is brain penetrant, occupying 
about 50% of mGluR5 after 10 mg/kg intraperitoneal (i.p.) dosing, and displays behavioral 
efficacy in a rat model of anxiety (223). 
Thus, VU0409106 provides us with the opportunity to determine whether selective 
mGluR5 inhibition immediately after traumatic stress can impede the development of PTSD-like 
symptoms in rats, possibly through attenuation of sleep-dependent emotional memory 
consolidation. In order to test this hypothesis, we first examined the effects of systemic 
VU0409106 administration on sleep-wake architecture and state-dependent qEEG power spectra 
in healthy rats. Then, we took advantage of the findings described in Chapter 2, and tested the 
effect of post-trauma VU0409106 treatment on SPS-induced alterations in contextual CF, sleep-
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wake architecture, qEEG power spectra, body temperature, and amygdala 5-HT utilization, as 
well as the induction of amygdala early growth response protein 1 (EGR-1), a key molecular 
mediator of emotional memory consolidation (33). 
 
Methods 
 
Subjects 
All male Sprague-Dawley rats (Harlan, Indianapolis, IN) used in the present studies were 
housed under a 12 hour light:12 hour dark cycle and given ad libitum access to food and water. 
All animal experiments were approved by the Vanderbilt University Animal Care and Use 
Committee and experimental procedures conformed to guidelines established by the National 
Research Council Guide for the Care and Use of Laboratory Animals. All efforts were made to 
minimize animal suffering and the number of animals used. 
 
Compound 
 3-fluoro-N-(4-methylthiazol-2-yl)-5-(pyrimidin-5-yloxy)benzamide (VU0409106) was 
synthesized in house as previously described (295), and dissolved in 10% Tween 80 vehicle, 
creating a microsuspension prior to intraperitoneal (i.p.) administration at a volume of 2mL/kg.  
 
EEG Surgery 
Rats (250-375 grams) were surgically implanted with a telemetric transmitter (4-ET, Data 
Sciences International, St. Paul, MN) for recording EEG, electromyography (EMG), and body 
temperature. Under isoflurane anesthesia (3% induction; 1.5-2.5% maintenance) the transmitter 
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was implanted subcutaneously across the back of each rat. Transmitter leads were tunneled 
subcutaneously to the skull. After holes were drilled in the skull, the exposed wires were placed 
in contact with the dura and secured in place with dental cement (Butler Schein, Dublin, OH). 
Three sets of leads were placed bilaterally to record from cortical regions corresponding to the 
frontal, parietal, and occipital cortices (+2 mm, -2 mm, and -6mm anterior-posterior from 
Bregma, respectively and +/- 2 mm lateral to the midline). An additional set of leads was placed 
bilaterally in the nuchal muscles for EMG recording. Rats were individually housed following 
surgery and allowed to recover and acclimate to the recording room for a minimum of 10 days 
prior to testing.  
 
EEG 
For experiments testing the effect of VU0409106 on sleep-wake architecture and qEEG 
spectral power in non-stressed rats, each rat was randomized into vehicle, 3mg/kg VU0409106, 
10mg/kg VU0409106, or 30mg/kg VU0409106 dose groups. Baseline recordings were begun at 
the start of the light phase, then the appropriate compound was administered two hours later, and 
recordings were allowed to continue for the remainder of the twenty-four hour period. In a partial 
crossover design, each rat received two different doses or vehicle, allowing for a 5 day washout 
period between compound administrations. 
 
Spontaneous locomotor activity 
 Spontaneous locomotor activity was conducted in open-field chambers (27 × 27 × 20 cm) 
(Hamilton Kinder) equipped with 16 horizontal (x- and y-axes) infrared photobeams. Changes in 
locomotor activity were measured as the number of photobeam breaks per five minutes, and 
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were recorded with a Pentium I computer equipped with rat activity monitoring system software 
(Hamilton Kinder). Rats were pretreated with vehicle or VU0409106, (3, 10, or 30 mg/kg, i.p.) 
then placed individually into each chamber 30 minutes later. Locomotor activity was assessed for 
thirty minutes.  
 
Rotarod 
The effects of VU0409106 on motor performance were evaluated by using a rotarod 
(MED Associates, St. Albans, VT). All rats were given an initial training trial of 120 seconds, 
followed by two additional training trials of 85 seconds, approximately 10 min apart, using a 
rotarod (7.5 cm in diameter) rotating at a constant speed of 20 revolutions/min. After initial 
training trials, a baseline trial of 120 s was conducted, and any rats that did not reach the 120 
second criteria were excluded from the study. Rats were then treated with vehicle or VU0409106 
(3, 10, or 30 mg/kg i.p.), and tested 30 min later. The time each animal remained on the rotarod 
was recorded, and animals that did not fall off of the rotarod were given a maximal score of 120 
seconds. 
 
Experimental design for post-trauma intervention studies 
For determining the effects of VU0409106 on SPS-induced alterations in the CF 
response, rats were randomized to receive either SPS or SHAM treatment followed immediately 
by administration of vehicle or VU0409106, (3, 10, or 30 mg/kg, i.p.). Fifteen days later, all rats 
underwent fear conditioning; one day after that, they were tested for their freezing response. 
For testing the effect of VU0409106 administration on SPS-induced EEG alterations, 
each rat was randomized into either SPS/Vehicle or SPS/VU0409106 groups. Two continuous 24 
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hour baseline (BL) recordings were performed for each rat in its home cage to serve as within-
subjects comparator for all subsequent sleep-wake, qEEG, and body temperature data. After BL 
recordings, each rat received SPS treatment and was administered either 10 mg/kg VU0409106 
or vehicle within 30 minutes of SPS completion. Home cage recordings were immediately re-
initiated in both groups (Day 0), continued for two days (Days 1 and 2) after which transmitters 
were turned off, then reactivated on Day 7. Subsequent off-line analysis of sleep-wake and qEEG 
data was divided into the remaining hours of Day 0, or in 24hr intervals comprising Days 1, 2, 
and 7 post-SPS treatment.  
For testing the effect of VU0409106 administration on SPS-induced alterations in 
biochemistry and neurochemistry, rats were randomized to receive either SPS or SHAM 
treatment followed immediately by administration of vehicle or 10 mg/kg VU0409106, i.p. 
SHAM rats were sacrificed thirty minutes after dosing; SPS rats were sacrificed either thirty 
minutes, (Day 0), one day (Day 1), or seven days (Day 7) after dosing. On the day of sacrifice, 
rats were briefly anesthetized with isoflurane and decapitated. Hippocampus, amygdala, and PFC 
were dissected, rapidly frozen on dry ice, and stored at −80 °C for tissue mRNA and 
neurochemistry experiments. Trunk blood was collected into heparin-lined tubes, and then 
centrifuged at 5,000 rpm for 9 minutes at 4 °C to obtain plasma. 
Figure 17A depicts the experimental design for behavioral studies (Cohort 1), EEG 
studies (Cohort 2), and tissue collection studies (Cohort 3). For all experiments, SPS and SHAM 
treatment occurred within the first 6 hours of the light phase. Figure 17B shows the chemical 
structure of VU0409106. 
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Single Prolonged Stress 
SPS was performed according to Liberzon et al. (315). Briefly, rats were restrained for 2 
hours, followed by forced swim for 15 minutes in 24 ⁰C water. Following a 15 minute recovery 
period, rats were exposed to diethyl ether vapor in a bell jar until anesthesia. The SPS model did 
not cause mortality. SPS did illicit hallmarks of the rodent stress response such as porphyrin 
staining of the eyes, and urination and defecation. There were no major individual differences 
observed in these parameters during each experiment, and no inclusion or exclusion criteria were 
applied prior to the start of EEG recordings or tissue collection. SHAM treatment consisted of 
brief handling in a novel procedure room. All animals were placed into fresh cages after 
treatment.  
 
Contextual CF 
 Fear conditioning and testing were performed in sound attenuating chambers equipped 
with a stainless steel grid floor for shock delivery and a video camera for recording freezing 
behavior (MedAssociates, Allentown, NJ). For determining the effects of VU0409106 on SPS-
induced alterations in the CF response, rats were randomized to receive either SPS or SHAM 
treatment followed immediately by i.p. administration of vehicle or VU0409106, (3, 10, or 30 
mg/kg, i.p.). Fifteen days later, all rats underwent fear conditioning to the chamber context 
consisting of a 3 minute habituation period followed by a 4 second, 0.8 mA footshock, and 
ending with a 1 minute undisturbed period after which each rat was returned to its home cage. 
One day later, all rats were reexposed to the same chambers, and freezing behavior, defined as 
motionless posture excluding respiratory movements, was measured in the absence of any shock 
stimuli for 5 minutes.  
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Figure 17. Experimental design for post-trauma intervention studies with VU0409106. (A) 
In cohort 1, non-implanted rats were exposed to either single prolonged stress (SPS) or SHAM 
treatment immediately followed by systemic i.p. administration of either vehicle or 10 mg/kg 
VU0409106. Fifteen days later, all rats underwent contextual fear conditioning (CFC Train); one 
day later they were reexposed to the context in the absence of shock and freezing response was 
measured (CFC Test). In cohort 2, continuous EEG, EMG, and temperature data were 
telemetrically recorded from chronically implanted rats throughout successive 24 hour light-dark 
cycles (ON: 6:00AM; OFF: 6:00PM) before (BL) and several days after (Days 0, 1, 2, and 7) 
SPS with systemic i.p. administration of either vehicle or 10 mg/kg VU0409106 immediately 
after treatment. SPS treatment was performed within the first 6 hours of the light phase on Day 0 
during which recording was not possible; EEG data from this day was re-initiated when each 
animal was returned to its home cage. In cohort 3, non-implanted rats underwent either SPS or 
SHAM treatment immediately followed by systemic i.p. administration of either vehicle or 10 
mg/kg VU0409106. SHAM rats were sacrificed thirty minutes after dosing; SPS rats were 
sacrificed either thirty minutes, (Day 0), one day (Day 1), or seven days (Day 7) after dosing. (B) 
Chemical structure of VU0409106. 
 
 
 To determine whether VU0409106 impairs the consolidation of normal fear learning, a 
separate group of rats having received no prior treatment other than handling underwent fear 
conditioning to the chamber context consisting of a 1 minute habituation period followed by 
three 1 second, 0.5 mA footshocks with 1 minute inter-shock intervals, and ending with a 1 
minute undisturbed period. Immediately after removal from the chamber, each rat was 
administered vehicle or VU0409106, (3, 10, or 30 mg/kg, i.p.), after which it was returned to its 
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home cage. One day later, all rats were reexposed to the same chambers, and freezing behavior, 
defined as motionless posture excluding respiratory movements, was measured in the absence of 
any shock stimuli for 5 minutes. 
 
Tissue collection 
For biochemical and neurochemical endpoints, a group of non-implanted rats was 
randomly assigned to SHAM treatment or one of three SPS groups (Day 0, 1 or 7). Rats were 
briefly anesthetized with isoflurane, and sacrificed by decapitation either immediately (Day 0), 
one day (Day 1), or seven days (Day 7) after SPS; SHAM rats were sacrificed immediately after 
SHAM treatment. Hippocampus, PFC, and amygdala were dissected, rapidly frozen on dry ice, 
and stored at −80 °C for tissue neurochemistry. Trunk blood was collected into heparin-lined 
tubes, and then centrifuged at 5,000 rpm for 9 minutes at 4 °C to obtain plasma. 
 
Tissue neurochemistry 
Tissue concentrations of 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) 
were determined by HPLC-ECD as described previously (316).  5-HT utilization was calculated 
as 5-HIAA/5-HT in ng/mg protein. 5-HT, 5-HIAA, and 5-HT utilization values were then 
normalized to the SHAM/Vehicle group average. Values greater than 3 standard deviations from 
the mean for 5-HIAA and 5-HT utilization were excluded. 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Alterations in mRNA expression levels of EGR-1, brain-derived neurotrophic factor 
(BDNF), NR1, NR2A, and NR2B were measured using Aqueous Micro kits (Life Technologies, 
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Grand Island, NY) for RNA extraction, NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE) for RNA quantification, QuantiTect Reverse Transcription Kit 
(QIAGEN, Hilden, Germany) for complementary DNA transcription, CFX96 Real-Time PCR 
Detection System (Bio-Rad, Hercules, CA) using primers from TaqMan Gene Expression 
Assays (Life Technologies) for qRT-PCR. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as an internal control; data are presented using the comparative cycle 
threshold (CT) method normalized to SHAM-treated rats. 
 
Plasma corticosterone 
Corticosterone, the rodent analogue of the human glucocorticoid cortisol, was measured 
using a double antibody radioimmunoassay (RIA) kit (MP Biomedicals, Orangeburg, NY). 
 
Sleep staging 
EEG, EMG, and temperature data were collected with Dataquest A.R.T. 4.3 software 
(DSI, Minneapolis, MN) using a continuous sampling method. Telemetric data were sampled at a 
rate of 500 Hz and transmitted via a receiver (RPC-2, DSI) placed below the cage of each rat. 
Each receiver was connected to a data exchange matrix (DSI) which transferred EEG, EMG, and 
temperature data to a computer for off-line analysis. Two trained observers used Neuroscore 3.0 
software to manually stage each 10 second epoch as wake, NREM, or REM sleep based on 
accepted characteristic EEG and EMG oscillatory patterns (317). All 10 second epochs were 
summed into 2 hour bins. For the acute effects of VU0409106 administration on SPS treatment 
on Day 0, 2 hour bins were group averaged to examine the amount of time spent in wake, 
NREM, or REM sleep. To assess the prolonged effects of VU0409106 administration on SPS 
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treatment (Days 1, 2, and 7), 12 hour bins comprising either the light or dark phase of a given 
day were group averaged. 
 
qEEG spectral power analysis 
qEEG relative power spectra from frontal and parietal electrodes were computed for each 
rat and on each day of recording in 10 second epochs grouped into conventional power bands 
(delta δ: 0.5-4.9 Hz, theta θ: 5-8.9 Hz, alpha α: 9-13.9 Hz, beta β: 14-29.9 Hz, low gamma γ: 30-
49.9 Hz, and high γ: 50-100 Hz) (227) using a Fast Fourier Transform with a Hamming window 
and overlap ratio of 0.5. Relative power within each band was calculated as a percent of total 
power, then binned by stage (wake, NREM, or REM). The percent change from the BL value of 
the same power band for the same rat during the corresponding sleep-wake stage was then 
calculated for each individual rat and group averaged. For the acute effects of VU0409106 
administration on healthy rats, BL values refer to an average of values collected during the first 
two hours of the light phase recorded on the day of treatment, in twenty minute bins. For the 
effects VU0409106 administration on SPS treatment, BL values refer to an average of those 
gathered during the two BL recording days in twelve hour bins. Slow wave activity (SWA) was 
defined as relative delta power in the frontal cortex during NREM sleep. Equipment error 
prevented recording from the frontal lead of one rat in each of the SPS/Veh and SPS/VU0409106 
groups, and from the parietal lead of one rat in the SPS/Veh group. 
 
Statistical analysis 
For the acute effects of VU0409106 on sleep-wake architecture, qEEG spectral power, 
temperature, and spontaneous locomotor activity in non-stressed rats, as well as the effects of 
 70 
post-SPS VU0409106 administration on short and long-term sleep-wake architecture, qEEG 
spectral power, and temperature, a repeated measures two-way analysis of variance (ANOVA) 
was applied; if significant, a Bonferroni post hoc test was performed with significance defined as 
P < .05. For the acute effects of VU0409106 on rotarod performance and normal fear learning, 
and for the effects of SPS on EGR-1 expression in the amygdala, a one-way ANOVA was 
applied; if significant, a Dunnett’s post hoc test was used with significance defined as P < .05. 
For the effects of post-SPS VU0409106 administration on contextual CF, 5-HT utilization, and 
plasma corticosterone concentration, a two-way ANOVA was applied; if significant, a 
Bonferroni post hoc test was performed with significance defined as P < .05. For the effects of 
post-SPS VU0409106 administration on sleep latencies, a student’s t test was applied with 
significance defined as P < .05. 
 
Results 
 
mGluR5 antagonism preferentially suppressed REM sleep. 
 VU0409106 modestly increased time spent awake only at the highest dose of 30 mg/kg 
(Figure 18A) (time [F11,363 = 91.10, P < 0.0001], dose [F3,33 = 11.98, P < 0.0001], interaction 
[F33,363 = 1.62, P = 0.02]), and there was a main effect of time and dose on NREM sleep 
(Figure 18B) (time [F11,363 = 91.41, P < .0001], dose [F3,33 = 13.88, P < .0001]), but no time 
point reached post-hoc significance. The most significant effect of VU0409106 was a dose-
dependent suppression of time spent in REM sleep (Figure 18C) (time [F11,363 = 35.38, P < 
.0001], interaction [F33,363 = 4.88, P < .0001]). 
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mGluR5 antagonism increased waking high gamma power and NREM sleep delta power in 
the frontal cortex. 
 Similar to NMDA receptor antagonists (279), VU0409106 dose-dependently increased 
high gamma power during wake (Figure 19A) (time [F30,1046 = 6.46, P < .0001], dose [F3,1012 
= 32.57, P < .0001], interaction [F90,1012 = 2.25, P < .0001]). Also similar to NMDA receptor 
antagonists, and consistent with an improvement in sleep quality (263, 277, 278), VU0409106 
dose-dependently increased delta power during NREM sleep (aka SWA) (Figure 19B) (time 
[F30,1012 = 21.34, P < .0001], dose [F3,1012 = 32.57, P < .0001], interaction [F90,1012 = 2.25, 
P < .0001]). 
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Figure 18. VU0409106 selectively suppressed REM sleep. (A) VU0409106 administration 
modestly increased time spent in wake at the highest dose of 30 mg/kg, i.p., but (B) had no 
significant effect on NREM sleep time. (C) By contrast, VU0409106 preferentially and dose-
dependently reduced REM sleep time for up to several hours. Black bar indicates dark phase. 
Data are depicted as mean ± SEM (n = 8-10). Comparison between doses performed by repeated 
measures two-way ANOVA. ^^ P < 0.01, 3mg/kg vs. Veh; **P < 0.01, 10 mg/kg vs. Veh; #P < 
0.05, ##P < .01, ####P < .0001, 30 mg/kg vs. Veh in Bonferroni post hoc test.   
 73 
 
Figure 19. VU0409106 increased waking high gamma power and NREM sleep delta power 
in the frontal cortex. (A) Relative to baseline, VU0409106 administration dose-dependently 
increased high gamma power in the frontal cortex during wake, and (B) delta power during 
NREM sleep, a measure referred to as slow wave activity (SWA). Data are depicted as mean ± 
SEM (n = 9-10). Comparison between doses performed by repeated measures two-way ANOVA. 
^ P < 0.05, 3mg/kg vs. Veh; *P < 0.05, 10 mg/kg vs. Veh; #P < 0.05, 30 mg/kg vs. Veh in 
Bonferroni post hoc test.   
 74 
mGluR5 antagonism caused dose-dependent reductions in body temperature and sedation. 
 In order to effectively determine whether post-trauma VU0409106 administration could 
prevent PTSD-like symptoms in the studies described below, we first attempted to select a dose 
that did not induce significant adverse effects. Antagonists of both NMDA receptors and mGluR5 
have been shown to cause reductions in body temperature, induce sedation, and impair 
locomotor activity in rodents (337, 338), so we first determined whether VU0409106 also 
exhibits this liability. Systemic administration of VU0409106 caused acute reductions in body 
temperature during wake (Figure 20A) (time [F24,792 = 7.24, P < .0001], dose [F3,792 = 15.63, 
P < .0001], interaction [F72,792 = 3.41, P < .0001]) and NREM sleep (Figure 20B) (time [24,769 
= 5.12, P < .0001], dose [F3,769 = 19.90, P < .0001], interaction [F72,769 = 3.72, P < .0001]). 
Time spent in REM sleep was so reduced that no temperature data for this state could be 
gathered during the hours after VU0409106 administration (Figure 20C). VU0409106 also dose-
dependently decreased spontaneous locomotor activity (Figure 20D) (time [F5,140 = 75.29, P < 
.0001], interaction [F15,140 = 3.47, P < .0001]), and reduced the latency to fall in a rotarod test 
(Figure 20E) (F3,20 = 3.18, P = .05) indicating sedation. Given the insomnia-like effects induced 
by SPS reported above, however, mild sedation could be an advantageous property for a 
compound intended to intervene in posttraumatic symptoms. Since 10 mg/kg VU0409106 
exhibited modest sedation in the spontaneous locomotor assay, but impaired motor function to a 
lesser degree than the 30 mg/kg dose in the rotarod assay, this dose was chosen for the post-SPS 
dosing experiments described below.  
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Figure 20. VU0409106 caused dose-dependent reductions in body temperature and 
sedation. (A) Relative to baseline, VU0409106 acutely decreased body temperature during wake 
and (B) NREM sleep, but not (C) REM sleep, which was suppressed such that few data points 
could be collected for temperature. (D) VU0409106 also inhibited spontaneous locomotor 
activity in an open field, and (E) induced modest motor impairments at the highest dose of 30 
mg/kg in the rotarod test. Data are depicted as mean ± SEM (n = 9-10 for A-C, 6-8 for D,E). 
Comparison between doses performed by repeated measures two-way ANOVA for A-D, and 
one-way ANOVA for E. ^ P < 0.05, ^^ P < 0.01, 3mg/kg vs. Veh; *P < 0.05, **P < 0.01, ***P < 
0.001, 10 mg/kg vs. Veh; #P < 0.05, ##P < .01, ###P < .001, ####P < .0001, 30 mg/kg vs. Veh 
in Bonferroni post hoc test for A-D, and Dunnett’s post hoc test for E.   
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Post-trauma mGluR5 antagonism inhibited the development of augmented threat 
responding without disturbing normal threat learning. 
 Similar to previous reports (59, 339), SPS induced an augmented threat response as 
measured by contextual CF (Figure 21A). However, this exaggerated threat response was 
attenuated in rats that received VU0409106 immediately after SPS (Figure 21A) (treatment 
[F1,80 = 6.88, P = 0.01], interaction [F3,80 = 2.84, P = .04]), with 10 mg/kg VU0409106 being 
the most effective dose. VU0409106 administered after SHAM treatment did not affect 
contextual CF (Figure 21A). In addition to its ameliorative effect on SPS-induced augmentation 
of threat learning, VU0409106 left intact the consolidation of normal threat learning when 
administered after contextual CF (Figure 21B) in rats that had not undergone SPS treatment 
(experimental design depicted in Figure 21C). 
 
Post-trauma mGluR5 antagonism acutely extended REM sleep suppression. 
 Consistent with our previous findings, SPS significantly increased time spent in wake 
(Figure 22A) (time [F21,294 = 36.02, P < .0001]), and reduced time spent in NREM sleep 
(Figure 22B) (time [F21,294 = 50.81, P < .0001]) relative to BL. 10 mg/kg VU0409106 had no 
significant effect on wake or NREM sleep time, but further reduced time spent in REM sleep 
(Figure 22C) (time [F21,294 = 27.80, P < .0001], interaction [F21,294 = 2.10, P = .0037]) 
relative to vehicle-treated rats. In addition, 10 mg/kg VU0409106 significantly reduced the 
latency to NREM sleep after SPS (Figure 23A) (t = 2.95, p = .01), and increased the latency to 
REM sleep after SPS (Figure 23B), and after the onset of NREM sleep (Figure 23C) (t = 2.96, p 
= .01). 
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Figure 21. Post-trauma VU0409106 inhibited the development of trauma-induced 
augmented threat responding without disturbing normal threat learning. (A) SPS caused 
augmented threat responding in the contextual CF assay relative to SHAM rats fifteen days after 
treatment; this effect was attenuated if VU0409106 had been administered immediately after 
SPS. (B) VU0409106 did not induce a general amnesic effect, however, leaving normal threat 
responding intact (C) when administered immediately after contextual CF training. Data are 
depicted as mean + SEM (n = 10-11).Comparison between doses performed by two-way 
ANOVA for A, and one-way ANOVA for B. **P < 0.01, SPS/Veh vs. SHAM/Veh; *P < 0.05, 
SPS/10 mg/kg VU0409106 vs. SPS/Veh in Bonferroni post hoc test.   
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Figure 22. Post-trauma VU0409106 acutely extended REM sleep suppression. (A) 
VU0409106 had no effect on acute SPS-induced increases in wake or (B) decreases in NREM 
sleep relative to baseline (BL), but (C) further reduced REM sleep time for up to several hours 
after SPS relative to vehicle treated rats. Black bars indicate dark phases. Data are depicted as 
mean ± SEM (n = 8). Comparison between groups performed by repeated measures two-way 
ANOVA. *P < 0.05, 10 mg/kg vs. Veh in Bonferroni post hoc test.  
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Figure 23. Post-trauma VU0409106 decreased NREM sleep latency and increased REM 
sleep latency. (A)VU0409106 significantly decreased the latency to first enter NREM sleep after 
SPS, (B) non-significantly increased the time to enter REM sleep after SPS, and (C) significantly 
increased the latency to enter REM sleep after first NREM sleep bout. Data are depicted as mean 
+ SEM (n = 8). Comparison between groups performed by t test, *P < 0.05.  
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Post-trauma mGluR5 antagonism modestly attenuated subsequent sleep reduction and 
fragmentation. 
 Consistent with our previous findings, and possibly indicative of an insomnia-like 
phenotype, SPS caused significant increases in time spent awake during the light phase on Days 
1 and 2 (Table 4) (time [F3,42 = 27.93, P < .0001]), culminating in an increased number of bouts 
(time [F3,42 = 2.44, P < .0001]) and longer average bout lengths (time [F3,42 = 10.08, P < 
.0001]). These changes in wake were accompanied by reductions in light phase NREM sleep 
time (time [F3,42 = 16.33, P < .0001]), increased NREM sleep bout number (time [F3,42 = 
14.51, P < .0001]), and decreased NREM sleep average bout length (time [F3,42 = 21.85, P < 
.0001]), as well as decreased REM sleep time (time [F3,42 = 14.9, P < .0001]), and a main effect 
on REM sleep average bout length (time [F3,42 = 3.84, P = .02]). This fragmentation of NREM 
and REM sleep during the light phase was modestly attenuated by prior administration of 10 
mg/kg VU0409106 post-SPS which decreased the number of wake bouts, and increased their 
average length (dose [F1,14 = 4.88, P = .04]). Post-trauma 10 mg/kg VU0409106 also attenuated 
subsequent reductions in light phase REM sleep time (dose [F1,14 = 5.67, P = .03]) relative to 
rats that had received vehicle after SPS.  
 During the dark phase, SPS induced significant reductions in wake time on Days 1 and 2 
(Table 4) (time [F3,42 = 252.56, P < .0001])), along with increases in bout number (time [F3,42 
= 18.21, P = .0002]) and reductions in average bout length (time [F3,42 = 14.13, P < .0001]). 
SPS also caused persistent increases in NREM sleep time (time [F3,42 = 35.90, P < .0001]) and 
bout number (time [F3,42 = 8.03, P = .0002]) during the dark phase, as well as increases in REM 
sleep time (time [F3,42 = 39.02, P < .0001]), bout number (time [F3,42 = 10.84, P < .0001]), and 
average bout length (time [F3,42 = 7.45, P = .0004]). Rats that received 10 mg/kg VU0409106  
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Table 4. Post-trauma mGluR5 antagonism modestly attenuated subsequent sleep disturbances. 
LIGHT PHASE  Treatment BL SPS Day 1 SPS Day 2 SPS Day 7 
Time (min) 
WAKE 
Vehicle 200.3 ± 6.9 238.7 ± 7.2 224.6 ± 9.9 202.2 ± 7.5 
VU0409106 203.5 ± 6.9 249.4 ± 9.9 238.3 ± 8.6 219.2 ± 10.1 
NREM 
Vehicle 435.7 ± 5.0 415.0 ± 5.8 423.1 ± 8.6 438.1 ± 6.6 
VU0409106 423.2 ± 7.6 391.2 ± 8.5 406.3 ± 8.7 410.8 ± 8.5 
REM 
Vehicle 83.5 ± 2.1 66.2 ± 3.1 72.4 ± 3.5 79.9 ± 3.5 
VU0409106 93.6 ± 4.7 79.5 ± 3.2* 75.2 ± 5.0 89.5 ± 3.9 
 No. bouts per 
hour 
WAKE 
Vehicle 13.8 ± 0.5 15.9 ± 0.7 16.2 ± 0.9 12.3 ± 0.5 
VU0409106 13.7 ± 0.6 14.3 ± 0.6 13.4 ± 0.7* 11.6 ± 0.7 
NREM 
Vehicle 14.0 ± 0.4 16.1 ± 0.7 16.2 ± 0.9 12.4 ± 0.5 
VU0409106 14.0 ± 0.6 14.5 ± 0.6 13.4 ± 0.6* 11.7 ± 0.7 
REM 
Vehicle 4.1 ± 0.1 3.5 ± 0.2 3.9 ± 0.4 3.7 ± 0.1 
VU0409106 5.3 ± 0.2 3.9 ± 0.1 4.1 ± 0.3 4.4 ± 0.3 
Bout length 
(sec) 
WAKE 
Vehicle 72.2 ± 3.0 76.1 ± 4.7 71.3 ± 5.3 83.1 ± 4.4 
VU0409106 73.1 ± 3.0 87.2 ± 3.7 90.1 ± 4.6* 98.1 ± 7.1 
NREM 
Vehicle 159.2 ± 6.8 131.8 ± 5.5 134.5 ± 7.0 181.2 ± 6.8 
VU0409106 158.8 ± 8.0 137.9 ± 7.2 156.4 ± 9.5 184.1 ± 13.3 
REM 
Vehicle 100.2 ± 2.7 95.6 ± 5.5 107.9 ± 2.6 106.4 ± 7.2 
VU0409106 104.3 ± 5.3 104.0 ± 5.4 94.3 ± 6.3 106.4 ± 7.2 
DARK PHASE  Treatment BL SPS Day 1 SPS Day 2 SPS Day 7 
Time (min) 
WAKE 
Vehicle 476.5 ± 13.1 407.4 ± 21.6 439.5 ± 18.9 453.9 ± 14.6 
VU0409106 473.7 ± 8.0 384.8 ± 12.8 431.7 ± 8.5 465.8 ± 12.6 
NREM 
Vehicle 217.5 ± 10.7 270.8 ± 18.1 247.2 ± 15.2 236.1 ± 12.3 
VU0409106 214.5 ± 8.0 280.6 ± 14.2 243.6 ± 8.7 218.9 ± 11.5 
REM 
Vehicle 25.9 ± 3.1 41.7 ± 4.2 33.1 ± 4.2 29.4 ± 3.3 
VU0409106 31.6 ± 2.2 54.4 ± 4.2* 44.6 ± 2.0 35.3 ± 2.5 
 No. bouts per 
hour 
WAKE 
Vehicle 9.9 ± 0.6 10.7 ± 0.7 11.5 ± 0.8 8.9 ± 0.2 
VU0409106 9.9 ± 0.5 11.2 ± 0.4 9.8 ± 0.4 8.8 ± 0.4 
NREM 
Vehicle 9.8 ± 0.6 10.6 ± 0.7 11.4 ± 0.8 8.9 ± 0.3 
VU0409106 9.8 ± 0.5 11.2 ± 0.4 9.7 ± 0.4 8.7 ± 0.4 
REM 
Vehicle 1.8 ± 0.2 2.3 ± 0.2 2.1 ± 0.2 2.1 ± 0.2 
VU0409106 2.1 ± 0.2 3.0 ± 0.2 2.9 ± 0.1* 2.7 ± 0.2 
Bout length 
(sec) 
WAKE 
Vehicle 244.9 ± 27.0 205.7 ± 20.6 201.1 ± 20.5 261.2 ± 14.2 
VU0409106 235.3 ± 14.7 177.2 ± 9.8 224.2 ± 6.6 275.7 ± 16.7 
NREM 
Vehicle 127.3 ± 7.4 130.5 ± 8.9 113.4 ± 10.3 134.4 ± 5.5 
VU0409106 122.0 ± 8.7 126.6 ± 5.9 126.9 ± 7.5 128.9 ± 8.5 
REM 
Vehicle 74.5 ± 7.6 87.0 ± 9.9 86.7 ± 9.9 69.9 ± 3.5 
VU0409106 73.6 ± 4.6 88.8 ± 4.4 78.6 ± 2.7 66.4 ± 4.0 
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after SPS exhibited further increased time spent in REM sleep (dose [F1,14 = 4.80, P = .04]), and 
increased REM bouts during the dark phase (dose [F1,14 = 7.02, P = .02]). 
 
Post-trauma mGluR5 antagonism blocked acute increases in frontal theta power during 
REM sleep and enhanced SWA. 
 Consistent with our previous findings, SPS induced dramatic acute increases in theta 
power during REM sleep in the frontal cortex during the light phase on Day 0, an effect that was 
almost completely attenuated by post-SPS administration of 10 mg/kg VU0409106 (Figure 24A) 
(time [F4,48 = 13.56, P < .0001], interaction [F4,48 = 5.21, P = .0014]). Also similar to our 
previous report, SPS caused an acute increase in light phase SWA measured in the frontal cortex 
on Day 0, but subsequently reduced this measure on Days 1 and 2 (Figure 24B) (time [F4,48 = 
62.10, P < .0001]). Rats that received 10 mg/kg VU0409106 after SPS exhibited significantly 
increased SWA on Day 0 relative to vehicle-treated rats (dose [F1,12 = 9.08, P = .01], interaction 
[F4,48 = 4.57, P = .0033]), but there was no effect on SWA reductions on Days 1 and 2 (Figure 
24B). VU0409106 did not alter REM sleep theta power in the frontal cortex in rats that had not 
received prior SPS (Figure 25A), nor did it modulate SPS-induced alterations in REM sleep theta 
power in the parietal cortex (Figure 25B) (time [F4,52 = 7.62, P < .0001]). Additionally, SPS-
induced increases in theta power were specific to REM sleep, being absent during wake in the 
frontal (Figure 25C) and parietal (Figure 25D) cortices. 
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Figure 24. Post-trauma VU0409106 blocked acute increases in frontal theta power during 
REM sleep and acutely enhanced SWA. (A)SPS treatment acutely increased theta power 
during REM sleep in the frontal cortex on Day 0; this effect was substantially attenuated by 
VU0409106 administration. (B) SPS also caused acute increases in delta power during NREM 
sleep in the frontal cortex (aka SWA); this effect was augmented by VU0409106 administration. 
SPS also caused modest reductions in SWA on Days 1 and 2, but this change was not reversed 
by prior VU0409106 administration. Data are depicted as mean + SEM (n = 7). Comparison 
between groups performed by repeated measures two-way ANOVA. ***P < 0.001, 10 mg/kg vs. 
Veh in Bonferroni post hoc test. 
 
 
 Post-trauma mGluR5 antagonism attenuated reductions in amygdala 5-HT utilization. 
 SPS caused a delayed reduction in 5-HT utilization in the amygdala beginning on Day 1; 
10 mg/kg VU0409106 administered immediately after SPS attenuated this reduction (Figure 
26B) (dose [F3,79 = 3.99, P = .05]). Consistent with our findings above, SPS also caused an 
acute increase in 5-HT utilization in the PFC (Figure 26C) (time [F3,79 = 8.12, P < .0001]) and 
hippocampus (Figure 26C) (time [F3,80 = 13.60, P < .0001]) on Day 0, but these increases were 
not affected by VU0409106 administration. 
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Post-trauma mGluR5 antagonism acutely inhibited SPS-induced hyperthermia with no 
effect on plasma corticosterone increases. 
 10mg/kg VU0409106 administered after SPS reduced subcutaneous body temperature, 
and prevented hyperthermia for several hours during wake (Figure 27A) (time [F57,798 = 30.64, 
P < .0001], interaction [F57,798 = 2.48, P < .0001]) and NREM sleep (Figure 27B) (time 
[F57,810 = 12.01, P < .0001], interaction [F57,810 = 2.96, P < .0001]), but not REM sleep 
(Figure 27C) (time [F56,763 = 7.72, P < .0001]). SPS-induced acute increases in body 
temperature were accompanied by increased circulating levels of corticosterone on Day 0 (Figure 
28) (time [F3,64 = 54.46, P < .0001], dose [F1,64 = 5.01, P = .03], interaction [F3,64 = 3.47, P = 
.02]).  
 
SPS induces amygdala expression of EGR-1. 
 In order to confirm that the deleterious effects of SPS are partially mediated by traumatic 
memory consolidation, we examined the effects of SPS on amygdala expression of EGR-1, a key 
molecular mediator of emotional memory (33). SPS acutely increased mRNA levels of EGR-1 in 
the amygdala on Day 0 relative to SHAM-treated rats (Figure 29) (F3,27 = 8.38, P = .0004).  
 
Discussion 
 In these studies, we demonstrated that the selective mGluR5 NAM VU0409106, when 
administered immediately after traumatic stress in rats, attenuates subsequent behavioral and 
physiological changes, possibly through acute suppression of REM-sleep dependent emotional 
memory consolidation. 
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We first showed that VU0409106 dose-dependently suppresses REM sleep in healthy 
rats, while leaving NREM sleep entirely intact. This effect differentiates mGluR5 antagonism 
from the effects of NMDA receptor antagonists, which at subanesthetic doses can inhibit both 
REM and NREM sleep (340). However, similar to NMDA receptor antagonists (263, 277-279), 
VU0409106 substantially and dose-dependently increased high gamma power during wake and 
delta power during NREM sleep in the frontal cortex. These effects are consistent with the 
functional coupling of mGluR5 and NMDA receptors (99-101, 103, 106, 107), and suggest that 
VU0409106 may partially exert its behavioral effects through downstream inhibition of NMDA 
receptors. Furthermore, NMDA receptor antagonist-induced increases in gamma power during 
wake and delta power during NREM sleep were recently employed as translational biomarkers 
of central target engagement and efficacy, respectively (263, 277-279). These exciting advances 
combined with our current findings suggest that this qEEG approach may also be available for 
the clinical development of novel mGluR5 NAMs.  
We next attempted to determine whether selective mGluR5 antagonism with VU0409016 
could inhibit the behavioral consequences of trauma when administered immediately after SPS.  
We found that post-SPS VU0409106 administration prevented the development of 
augmented threat responding, suggesting that mGluR5 inhibition after trauma could impede the 
progression of PTSD symptoms. We also found that VU0409106 extended SPS-induced REM 
sleep suppression consistent with the hypothesis that mGluR5 antagonism after trauma may 
prevent the development of PTSD-like hypervigilance through inhibition of REM sleep-
dependent emotional memory consolidation. VU0409106 administration after SPS not only 
reduced the amount of time spent in REM sleep, but also increased the latency to first enter REM 
sleep after NREM sleep onset. Importantly, it has been observed that REM sleep latency after 
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emotional learning can correlate strongly with behavioral measures of memory consolidation 
(240), possibly due to the existence of a critical temporal window for this process (31, 37). Due 
to an increased REM sleep rebound during the dark phase of Day 0, rats that were administered 
VU0409106 after SPS regained much of the REM sleep they had lost during the light phase of 
that day. This observation underlines the importance of the timing of REM sleep suppression 
after trauma for therapeutic purposes. It is likely that this REM sleep rebound occurred outside 
the temporal window during which emotional memory consolidation takes place (31, 37), and 
therefore did not lead to the subsequent manifestation of PTSD-like behavioral changes. This 
finding suggests that mGluR5 antagonist-mediated REM sleep suppression would lose its 
therapeutic effect if introduced several hours or days after trauma. Studies are ongoing to address 
this question, and to determine how long the temporal window for intervention after SPS might 
be.  
 In addition to suppressing the amount of time spent in REM sleep, VU0409106 also 
attenuated acute SPS-induced increases in theta power in the frontal cortex during REM sleep. 
Given that increased REM sleep theta power in the frontal cortex is a putative 
neurophysiological correlate of REM sleep-dependent emotional memory consolidation in both 
rodents (250) and humans (240), this finding strongly supports the interpretation that mGluR5 
inhibition exerts its therapeutic behavioral effect through blockade of traumatic memory 
consolidation. During post-trauma REM sleep, rhythmic activation of the amygdala at theta 
frequency likely promotes emotional memory consolidation through the induction of synaptic 
plasticity in the hippocampus and PFC, target brain structures known to oscillate at theta 
frequency in phase with the lateral amygdala, and to store long term emotional memory traces 
(250, 341, 342). Neuronal projections between the hippocampus, PFC, and lateral amygdala are 
 87 
glutamatergic (341), suggesting that VU0409106 may interfere with reciprocal entrainment of 
hippocampus, PFC and amygdala at theta frequency via post-synaptic mGluR5 inhibition in these 
regions, resulting in the observed attenuation of post-SPS increases in theta power during REM 
sleep, and possibly preventing the induction of synaptic plasticity associated with emotional 
memory consolidation (250, 341). VU0409106 administration in non-stressed rats did not reduce 
REM sleep theta power, suggesting that this effect is a specific blockade of trauma-induced 
alterations. This effect was also specific to the REM sleep state and to the frontal cortex, in 
support of the hypothesis that traumatic memory consolidation after SPS, and its attenuation by 
VU0401906, is heavily dependent on REM sleep-specific processes. Future studies are 
warranted aimed at determining whether SPS induces LTP at cortico-amygdala and 
hippocampal-amygdala synapses (33, 36, 37), and whether this plasticity is dependent on 
mGluR5-mediated increases in REM sleep theta power after trauma. 
 Consistent with the notion that VU0409106 prevents hyperactivation of the amygdala, we 
also found that this compound attenuated SPS-induced reductions in amygdala 5-HT utilization. 
As mentioned in Chapter 2, 5-HT exerts a net inhibitory influence on the lateral amygdala (325, 
326); the gradual reduction of 5-HT utilization caused by SPS, therefore, is hypothesized to 
contribute to amygdala hyperexcitability, a common finding in PTSD patients (29). One 
mechanism through which post-trauma mGluR5 antagonism may spare amygdala 5-HT content 
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Figure 25. VU0409106-mediated reductions in theta power only occurred after trauma 
specifically in the frontal cortex during REM sleep. (A) VU0409106 had no effect at any dose 
on theta power during REM sleep in the frontal cortex in rats that had not received any stress 
treatment. (B) SPS-induced acute increases in REM sleep theta power were less pronounced in 
the parietal cortex, and VU0409106 had no effect on this change. (C) SPS also had no significant 
effect on theta power during wake in the frontal cortex, or (D) in the parietal cortex. Data are 
depicted as mean ± SEM (n = 7-10). Comparison between groups performed by repeated 
measures two-way ANOVA.   
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Figure 26. Post-trauma VU0409106 non-significantly accelerated the normalization of beta 
power during wake while attenuating reductions in amygdala 5-HT utilization. (A) SPS 
treatment caused acute and persistent increases in beta power during wake in the frontal cortex; 
VU0409106 administration non-significantly accelerated the normalization of this change (n = 
7). (B) SPS treatment caused a concurrent reduction in amygdala 5-HT utilization starting on 
Day 1; this change was also blocked by VU0409106 administration. (C) VU0409106 
administration did not affect SPS-induced acute increases in 5-HT utilization in the PFC or (D) 
hippocampus (n = 9-13). Data are depicted as mean + SEM. Comparison between groups 
performed by repeated measures two-way ANOVA. *P < .05 SPS/VU0409106 vs. SPS/Veh in 
Bonferroni post hoc test.  
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Figure 27. Post-trauma VU0409106 acutely inhibited SPS-induced hyperthermia. (A) SPS 
caused acute and persistent hyperthermia during wake, (B) NREM sleep, and (C) REM sleep 
specifically during the light phase; VU0409106 significantly attenuated hyperthermia during 
wake and NREM sleep for several hours after SPS treatment. Data are depicted as mean ± SEM 
(n = 8). Comparison between doses performed by repeated measures two-way ANOVA. . ****P 
< .0001 SPS/VU0409106 vs. SPS/Veh in Bonferroni post hoc test.  
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Figure 28. Post-trauma VU0409106 had no effect on plasma corticosterone increases. SPS 
caused acute increases in circulating corticosterone on Day 0 relative to SHAM treatment. 
VU0409106 administration increased corticosterone levels in the plasma in SHAM treated rats, 
but had no effect on SPS-induced corticosterone increases. Data are depicted as mean + SEM (n 
= 9-10). Comparison between doses performed by repeated measures two-way ANOVA. **P < 
.01, ****P < .0001 in Bonferroni post hoc test.  
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Figure 29. SPS induces amygdala expression of EGR-1 and NMDA receptor subunits. 
Relative to SHAM-treated rats, SPS caused substantial increases in the mRNA levels of EGR-1 
in the amygdala on Day 0. This increase normalized by Day 1. SPS also increased expression of 
NR1 on Day 7, and NR2B on Days 0, 1 and 7. Data are depicted as mean + SEM (n = 8-9). 
Comparison between SHAM and SPS Day performed by one-way ANOVA. *P < 0.05, **P < 
0.01, *** P < 0.001 in Dunnett’s post hoc test compared to SHAM. 
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is by inhibiting the loss of serotonergic neurons in the dorsal raphe nucleus, the anatomical 
source of 5-HT in the amygdala (326). SPS has previously been shown to cause apoptosis in the 
dorsal raphe with cell death peaking at Day 7 (343), an observation that is consistent with our 
finding of delayed reductions in amygdala 5-HT utilization. Cell death in the dorsal raphe could 
be the result of excitotoxicity spurred by stress-induced release of excessive glutamate in this 
brain region (85), possibly originating from PFC or amygdala afferents (344, 345). VU0409106 
might counteract this process in the dorsal raphe by exerting neuroprotective effects similar to 
other mGluR5 antagonists (109, 335). It will be important in future studies to determine whether 
these changes in 5-HT utilization are specific to the lateral amygdala which is the predominant 
subregional target of serotonergic projections in the amygdala. 
Reduced 5-HT utilization in the amygdala, and the resulting disinhibition of this brain 
structure, could manifest as an increase in high frequency frontal cortical EEG oscillations 
during wake (327) which have been found to be elevated in PTSD patients and associated with 
hyperarousal (297-299). While we replicated our previous finding that, similar to these patients, 
waking beta power is increased up to seven days after SPS, VU0409106-treated rats did not 
exhibit a significant reduction in this measure. However, there was a trend toward more rapid 
normalization of waking beta power that coincided with attenuation of the loss of amygdala 5-
HT utilization. Replication of these studies is ongoing to determine whether mGluR5 antagonism 
after SPS can ameliorate this qEEG correlate of hyperarousal. 
  Another major effect of VU0409106 administration on SPS-induced alterations in qEEG 
power spectra was a dramatic acute enhancement of SWA. Consistent with our previous results, 
SPS caused an acute increase in SWA prior to a reduction in this measure on Days 1 and 2 that 
might reflect similar disturbances in the sleep quality of PTSD patients (300, 301, 321). Rats that 
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received VU0409106 after SPS displayed a further increase in SWA on Day 0 that coincided 
with reduced latency to NREM sleep onset after SPS. This finding suggests that the restorative 
properties of deep NREM sleep may be improved by post-trauma mGluR5 antagonism, an effect 
that could counteract the sleep disturbances and insomnia reported by recently traumatized 
individuals (287). Interestingly, NREM sleep and SWA increases are known to preferentially 
improve recall of declarative memories (225, 239, 245-249), offering the speculative 
interpretation that augmentation of this measure by mGluR5 inhibition may spare explicit 
memory for the declarative components of the previously experienced traumatic event while 
simultaneously inhibiting associated implicit negative emotions. In translating to the clinic, it 
may be more beneficial to attenuate implicit emotional reactivity to the traumatic memory rather 
than ablate explicit recall for the memory entirely. This assertion is supported by the observation 
that trauma victims who report peritraumatic amnesia and related dissociative symptoms may 
actually be at increased risk for PTSD development (14). With this potential caveat in mind, we 
demonstrated that multiple doses of VU0409106 administered after contextual CF do not block 
the consolidation of normal threat learning, lending further support to the interpretation that 
mGluR5 antagonism after SPS does not induce a general amnesic effect, possibly through sparing 
SWA. This effect differentiates mGluR5 antagonists from SSRIs and γ-aminobutyric acid A 
(GABAA) receptor PAMs, both classes of drugs which suppress REM sleep (346, 347), but 
which also acutely impair SWA (347, 348). GABAA PAMs such as benzodiazepines are known 
to be amnesic, and are actually contraindicated for the treatment of acute posttraumatic stress 
symptoms, possibly for this reason (291, 292, 349). 
 Preliminarily, we also found that SPS treatment results in the induction of EGR-1 in the 
amygdala, a molecular correlate of emotional memory consolidation (33). EGR-1 is an 
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immediate early gene and transcription factor, expression of which is required for initiating many 
of the cellular changes that are the substrates of memory consolidation after emotional learning  
(33). One product of EGR-1-mediated transcription is brain-derived neurotrophic factor (BDNF), 
which can promote increased expression of NMDA receptor subunits NR1, NR2A, and NR2B. 
We found that SPS had no significant effect on BDNF levels, but that subsequent to EGR-1 
expression increases, NR1 and NR2B mRNA levels in the amygdala were also increased, 
possibly contributing to the hyperactivity of this brain region and concomitant qEEG indices of 
hyperarousal on these days. EGR-1 expression has also been shown to be specifically increased 
during REM sleep after aversive associative conditioning (284, 350), suggesting that increased 
activity of this molecule may represent one mechanism through which traumatic memory is 
encoded in a sleep-dependent manner. Future studies are warranted aimed at determining 
whether EGR-1 and NMDA receptor protein levels are also increased in the amygdala, and 
whether post-trauma mGluR5 antagonism blocks its induction as a means of inhibiting emotional 
memory consolidation during REM sleep. 
 Taken together, these data suggest that selective mGluR5 antagonism after trauma may be 
a safe and effective means of inhibiting or preventing the development of PTSD symptoms. Our 
data also indicate that the potential therapeutic effects of this approach would be partially sleep-
dependent, and possibly grounded in the attenuation of traumatic memory consolidation. 
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CHAPTER 4 
 
DISCUSSION 
 
In this work, we have demonstrated that SPS offers a viable model of traumatic-stress 
induced physiological and behavioral changes similar to those exhibited by PTSD patients. In 
particular, rats which have undergone SPS display acute and persistent alterations in sleep-wake 
architecture and state-dependent qEEG spectral power indicative of PTSD-like symptoms. This 
model, therefore, provides the opportunity to test novel pharmacological interventions aimed at 
preventing these symptoms or treating them once they have already developed. We attempted the 
former approach by systemically administering the selective mGluR5 NAM VU0409106 
immediately after SPS with the hypothesis that this compound would block PTSD-like symptom 
development through attenuation of REM sleep-dependent traumatic memory consolidation. We 
found that a single dose of 10 mg/kg VU0409106 prevented the manifestation of augmented 
threat responding, a correlate of PTSD-related hypervigilance, and that this behavioral change 
was preceded by acute post-trauma REM sleep inhibition, and accompanied by normalization of 
5-HT signaling in the amygdala. These findings add to a growing literature in support of the 
hypothesis that PTSD symptoms may be prevented by early post-trauma intervention. This work 
also provides the first evidence that selective mGluR5 NAMs may represent one feasible target 
for this type of approach, and highlights the need to consider sleep effects in the development of 
this or other prophylactic drugs. 
The pharmacological prevention of PTSD symptoms would represent a major advance in 
the care of traumatized individuals, and would significantly reduce the societal burden of treating 
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thousands of chronic PTSD patients (4, 5). Despite the therapeutic potential demonstrated by the 
preclinical studies outlined above, however, there are significant hurdles that would need to be 
addressed for the clinical development of mGluR5 NAMs and other compounds aimed at 
inhibiting PTSD symptom progression after trauma. First, as mentioned, there is likely a 
restricted temporal window during which emotional memory consolidation could be blocked 
after experiencing trauma (31, 37, 284). This window may be as short as six hours, significantly 
limiting the amount of time that professional care givers would have to reach recently 
traumatized persons in need of prophylactic treatment. This limitation may be less of an 
impediment in certain populations at high risk for experiencing trauma, such as the military, in 
which victims of trauma are routinely reached within hours, and regimented care is rapidly 
initiated. Active members of the military in combat zones would likely be important partners in 
early proof-of-concept trials to determine whether post-trauma administration of clinically 
approved mGluR5 NAMs, such as fenobam (351), can prevent PTSD development. 
The fact that only about thirty percent of individuals who experience a traumatic event 
actually develop PTSD (5) represents another limitation to this preventive strategy. Based on this 
estimate, in the majority of traumatized individuals, prophylactic treatment with an mGluR5 
NAM or other compound would be unnecessary. This caveat would be especially important to 
consider for a drug with a narrow therapeutic index or high adverse effect liability. For care 
givers, this consideration would affect the cost-benefit analysis of drug treatment in the wake of 
trauma; it would be less tolerable to administer a drug that has potentially severe adverse effects 
to individuals at lower risk for PTSD development. Ideally, only those traumatized individuals 
known to harbor a predisposition for PTSD development would be given an mGluR5 NAM or 
other preventive drug. This problem could be addressed in two ways. First, it would be 
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advantageous to develop a drug that has modest adverse effect liability, such that the potential 
benefits of its administration are not outweighed by its risks. Whether this can be achieved is yet 
to be determined, but future research should emphasize the elimination of adverse effect liability 
in compounds, including mGluR5 NAMs, that show promise as inhibitors of emotional memory 
consolidation. Second, it would be important to determine what genetic and environmental 
factors contribute to PTSD vulnerability. Although significant resources are being dedicated to 
answer this question, it is as yet impossible to accurately predict who will get PTSD and who 
will not (352).  
Both of these endeavors could be served by the SPS model of PTSD symptoms. In 
particular, to determine susceptibility to PTSD, future studies could group rats into vulnerable 
and resistant subpopulations based on the magnitude or duration of change in one or more of the 
EEG alterations described above. Subsequent behavioral testing could be employed to determine 
whether these measures are indeed predictive, and whether there is a differential effect of 
mGluR5 antagonism on these two groups. For example, it is possible that the degree to which 
REM sleep theta power is increased in the hours after SPS predicts the likelihood or severity of 
augmented threat responding two weeks later. These types of studies would offer insight into the 
mechanisms of resilience while at the same time contributing to the possible discovery of 
translational methods for the prediction of PTSD susceptibility in humans. In the predator scent 
stress model, this use of cutoff criteria to define vulnerability and resilience in rats has been 
employed with interesting results (282, 353-358), and has been successfully used to test multiple 
pharmacological interventions for the prevention of PTSD-like symptoms (353, 355-358). 
Interestingly, in one study, post-trauma NMDA receptor antagonism with ketamine did not 
reduce the number of rats that went on to qualify as high responders in assays of PTSD-like 
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symptomology (358). This finding begs the question of whether ketamine would be equally 
ineffective in the SPS rodent model of traumatic stress, despite the efficacy of mGluR5 inhibition 
as described above. Future studies to test this hypothesis are warranted. 
Of note, SPS does not involve the use of ethologically relevant threats as with predator 
scent stress or social conflict. Nor does SPS incorporate threat from a conspecific during the 
traumatic experience. As such, despite portraying strong construct (59) and predictive validity 
(82, 339), the SPS model does not exhibit high levels of face validity as it relates to interpersonal 
trauma, such as physical or sexual assault. While traumas of this type generally result in higher 
rates of PTSD, and may cause more severe symptoms (359), it can be argued that traumas 
encountered during combat, vehicular accident, and natural disaster are not ethologically relevant 
to humans, and are not necessarily characterized by interpersonal interactions. Thus, SPS may 
more closely model trauma related to combat or disaster, and its effects may be more relevant to 
PTSD symptoms resulting from these types of traumatic experiences. As mentioned above, the 
clinical testing of prophylactic interventions for PTSD would be facilitated by the unique 
circumstances of military deployment; thus, the effects of SPS as reported here may be the best 
model for initially examining the benefits and risks of these interventions. 
An important unanswered question is whether total sleep deprivation after SPS would 
have the same ameliorative effects as mGluR5 NAM-mediated REM sleep suppression. We 
speculate that the unique profile of selective mGluR5 antagonism, which results in REM sleep 
suppression while simultaneously facilitating SWA during NREM sleep, is necessary to achieve 
the observed behavioral benefits. Indeed, acute insomnia is a common complaint of recently 
traumatized individuals, and has actually been correlated with subsequent risk for PTSD 
development (289). Insomnia is characterized primarily by a loss of NREM sleep enriched in 
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SWA (301, 321), suggesting that mGluR5 NAMs could counteract this effect while still 
inhibiting REM sleep-dependent emotional memory consolidation. In this way, the importance 
of simultaneous REM sleep suppression and NREM sleep facilitation could be explained by the 
preferential contribution of each of these sleep states to the consolidation of implicit and explicit 
memory, respectively (252). In experimental settings, recall for implicit and explicit components 
of a negative emotional memory can be dissociated such that prior stress enhances implicit recall 
for the affective components of the memory while simultaneously impairing explicit recall for 
the declarative components of the same memory (360). Victims of trauma can also exhibit 
enhanced implicit but not explicit memory for trauma-related information (17, 361). This 
phenomenon is especially striking in PTSD patients with trauma-related amnesia who exhibit the 
full spectrum of PTSD symptoms but demonstrate no explicit recall for the traumatic memory 
(14). With few exceptions (238), multiple lines of evidence demonstrate that the accumulation of 
REM sleep favors the consolidation of implicit memory (34, 225, 226, 234-239), while NREM 
sleep (and SWA) preferentially improves explicit memory (34, 225, 226, 234-239). This 
experimental observation, combined with the finding that peritraumatic amnesia predicts PTSD 
symptom severity (14), suggests that it may be beneficial to selectively suppress REM sleep 
during the aftermath of trauma in order to specifically inhibit overconsolidation of implicit 
negative feelings surrounding the traumatic memory, while sparing explicit recall for the event 
itself. Future studies could compare the effects of mGluR5 NAMs (REM sleep suppressing; 
NREM sleep sparing; SWA enhancing), SSRIs (REM sleep suppressing; NREM sleep 
suppressing; SWA impairing) (347), and benzodiazapenes (REM sleep suppressing; NREM 
sleep sparing; SWA impairing) (348) on SPS-induced behavioral and physiological alterations to 
determine which sleep-related factors are most important to engender a therapeutic effect. It is of 
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interest to note that even in the absence of pharmacological intervention, SPS resulted in an acute 
suppression of REM sleep and an increase in SWA, suggesting that these changes may be part of 
a failed adaptive response that is facilitated by mGluR5 antagonism.  
It could also be informative to determine whether non-pharmacological treatments aimed 
at specifically reducing REM sleep after SPS, such as the small platform method (362), have any 
therapeutic effects on the physiological or behavioral consequences of traumatic stress. If so, this 
finding would suggest that selective targeting of mGluR5 is not necessary, and that the 
ameliorative effects of inhibiting this receptor come primarily from REM sleep inhibition. 
Another means of testing this hypothesis would be to perform SPS during the rodent active 
phase, when there would be no need for sleep deprivation. It is possible that performing SPS at 
the beginning of the active phase would effectively delay the onset of sleep after trauma, and 
possibly attenuate subsequent symptoms. Support for this notion comes from the recent finding 
that this exact parametric manipulation ameliorated the behavioral effects of predator scent stress 
(282). Similarly, experimental sleep deprivation in healthy human subjects has been shown to 
preferentially impair consolidation of the implicit components of traumatic memory analogues 
(252). 
These questions arise from the fact that the studies above demonstrate a correlation 
between mGluR5 NAM-mediated REM sleep suppression and behavioral efficacy in a rodent 
model of trauma, but they do not show that REM sleep suppression is required for VU0409106 
to engender its therapeutic effect. The studies outlined in the previous two paragraphs would go 
some way toward addressing this question, but in order to demonstrate causality, post-SPS 
VU0409106 would have to be systemically administered while simultaneously preventing its 
inhibitory effects on REM sleep time and theta power. This could potentially be achieved by 
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optogenetically activating REM-on cells in the brainstem (363) while VU0409106 is present in 
relevant concentrations in the brain. In this study design, if post-trauma mGluR5 antagonism 
maintains its therapeutic behavioral effects, then REM sleep suppression is not required. 
However, we hypothesize that elimination of mGluR5 antagonist-mediated REM sleep changes 
would result in a loss or reduction of therapeutic effect, which would demonstrate a causal 
relationship between this component of VU0409106 and its benefits. 
In addition to suppression of REM sleep, mGluR5 antagonism may block emotional 
memory consolidation through attenuation of new protein synthesis in the amygdala. New 
protein synthesis in this brain region is required for the consolidation of emotional memory in 
rats (364), and selective inhibition of mGluR5 can inhibit new protein synthesis (365). Thus, it is 
possible that VU0409106 blocks new protein synthesis that would otherwise contribute to the 
remodeling of synapses in the neural fear circuitry, including the amygdala, preventing traumatic 
memory consolidation. Future studies aimed at determining whether SPS causes increased 
protein synthesis in the amygdala, and whether post-trauma administration of protein synthesis 
inhibitors such as anisomycin can exert similar therapeutic effects as VU0409106 would be 
informative.  
An alternative means of determining the role of mGluR5-mediated sleep alterations in 
traumatic memory consolidation would be to administer a compound that increases post-trauma 
REM sleep time or theta power, and determine whether the deleterious effects of SPS are 
exacerbated. This type of study would lend support to the hypothesis that REM sleep alterations 
affect the long term response to traumatic stress. To this end, in preliminary experiments, we 
attempted to positively modulate mGluR5 in an attempt to pharmacologically increase REM 
sleep in healthy rats, possibly providing an avenue to testing this hypothesis in the SPS model 
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(Appendix A). We systemically administered the selective mGluR5 PAM VU0409551 (366) to a 
group of healthy rats implanted with EEG electrodes, and recorded the effects of this compound 
on sleep-wake architecture. We found that selective mGluR5 activation resulted in dose-
dependent increases in time spent awake with concurrent reductions in both NREM and REM 
sleep. This increase in wake time may have been due to the fact that the neural circuitry that 
mediates wakefulness substantially overlaps with the brain regions that are activated to generate 
REM sleep, such as the LDT/PPT which exhibit mGluR5 expression (367). This observation 
precluded the use of this compound to test whether post-trauma pharmacological increases in 
REM sleep could exacerbate the effects of SPS. However, VU0409551 has been shown to 
potentiate mGluR5 signaling ex vivo without having any downstream effect on NMDA receptor 
activity (223). Thus, it is possible that an mGluR5 PAM that does not exhibit this signaling bias 
could potentiate both NMDA receptor activity and promote entry into REM sleep. This 
hypothesis is supported by our finding that systemic administration of D-cycloserine (DCS), a 
partial agonist of the strychnine-insensitive glycine binding (GlyB) site on the NMDAR, was 
capable of increasing time spent in REM sleep (Appendix A). In addition to being a potentially 
useful tool for testing the effect of pharmacological increases in REM sleep on traumatic 
memory consolidation, this finding opens another area of inquiry based on the observation that 
REM sleep promotes not only the consolidation of emotional memory, but also its extinction 
(241-244). 
Extinction learning represents the behavioral underpinning of exposure-based 
psychotherapy, and its pharmacological facilitation is a novel target for the treatment of PTSD 
(16, 242). If successful, this strategy would be capable of addressing the treatment resistant 
symptoms of PTSD patients who could not be reached quickly enough after experiencing a 
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traumatic event for prophylactic intervention. This approach would also be practicable without 
the discovery of predictive biomarkers for PTSD susceptibility because treatment would 
commence after the disorder has already developed. In both rodents and humans, the amount of 
REM sleep generated after extinction learning correlates with subsequent reductions in recall or 
reactivity to the memory (241, 243, 244). Thus, compounds that can increase REM sleep after 
successful exposure therapy sessions would be predicted to promote extinction of the traumatic 
memory and accelerate the reduction of associated symptoms. In support of this hypothesis, it 
was recently found that DCS administration modestly augmented the beneficial effects of 
exposure therapy in PTSD patients (89, 368). As mentioned in Chapter 1, these studies offer 
proof-of-concept validation for this therapeutic approach, but must be considered alongside other 
conflicting studies  (90). These discrepant results are likely due to the fact that DCS, a partial 
agonist for the GlyB site, can actually act as an antagonist of NMDA receptor activity (91), 
pointing to the need for an alternative means of safely facilitating NMDA receptors. 
Selective inhibition of the Glycine Transporter 1 (GlyT1) offers a different approach for 
the indirect positive modulation of NMDA receptors. Under normal conditions, the GlyB site on 
the NMDA receptor is not saturated due to the tightly controlled regulation of synaptic glycine 
levels by GlyT1, expressed in a distribution pattern that closely overlaps with NMDA receptor 
expression (92). Previous studies have demonstrated that selective inhibitors of GlyT1 can 
increase synaptic glycine levels sufficiently to produce enhanced NMDA receptor function in 
preclinical rodent models (93). Recently, we reported the development and characterization of a 
novel series of GlyT1 inhibitors, represented by ACPPBII, (2-amino-4-chloro-N-((4-phenyl-1-
(propylsulfonyl)piperidin-4-yl)methyl)benzamide), with suitable bioavailability, brain 
penetration, and physical properties for extensive characterization in vivo (94). Selective 
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inhibition of GlyT1 by ACPPBII may thus provide a novel target for enhancing the therapeutic 
effects of exposure therapy in PTSD patients. 
We performed preliminary experiments aimed at assessing this hypothesis in rats prior to 
testing ACPPBII in the SPS model. First, we demonstrated the potency and brain penetrance of 
ACPPBII relative to the prototypical GlyT1 inhibitor NFPS (N-[3-(4’-fluorophenyl)-3-(4’-
phenylphenoxy)propyl]sarcosine) (93) (Appendix A). Then, in opposition to the long term 
effects of SPS and consistent with a therapeutic profile of this compound, we found that 
ACPPBII increased 5-HT utilization in the amygdala. However, when we tested the effect of this 
compound on sleep-wake architecture, we found that ACPPBII increased time spent awake, and 
reduced time spent in NREM and REM sleep. This effect was likely caused by adverse motor 
effects such as compulsive walking and respiratory depression that manifested in a substantial 
reduction in spontaneous locomotor activity. These motor side effects are found in other GlyT1 
inhibitors, and are likely mediated by increased activation of the strychnine-sensitive inhibitory 
GlyA site on the glycine receptor which is expressed in the brain stem and mediates autonomic 
nervous system function (369). This toxicity, and the failure of ACPPBII to enhance REM sleep, 
likely contributed to our subsequent observation that, unlike the reported effects of DCS, 
ACPPBII failed to accelerate the acquisition or consolidation of extinction of context-mediated 
CF. Based on these studies, we determined that the therapeutic index of this compound was not 
conducive to further testing in the SPS model. 
In addition to the glutamatergic system, in preliminary experiments, we identified the 
histaminergic and orexinergic systems as potential targets for ameliorating the effects of SPS 
(Appendix B). As mentioned in Chapter 1, histamine and orexin release from hypothalamic 
neurons promotes transition to and maintenance of wakefulness, suggesting that SPS treatment 
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may induce an insomnia-like phenotype on Days 1 and 2 partially through augmentation of these 
neurotransmitter systems. Specifically, we found that SPS induced increased mRNA expression 
of orexin receptor subtype 1 (OxR1) in the PFC and hippocampus and orexin receptor subtype 2 
(OxR2) in the hippocampus in a time course that coincided with the persistent reductions in 
NREM and REM sleep time. This is consistent with the observation that increased orexin 
signaling contributes to wake promotion (227), and suggests that orexin antagonists such as the 
recently clinically approved compound suvorexant, could be an effective treatment for insomnia 
associated with chronic PTSD (370). Unlike benzodiazepines, suvorexant promotes NREM sleep 
time without reducing SWA (371), making it an especially attractive option for this application. 
However, it has been found that levels of the primary orexin signaling peptide, orexin A, are 
actually lower in the CSF of PTSD patients (372). Histamine also acts as a wake-promoting 
neurotransmitter (227), so we examined mRNA expression levels of the rate-limiting 
synthesizing enzyme for this molecule, histidine decarboxylase (HDC) in the hypothalamus. We 
found HDC expression was substantially decreased after SPS for at least seven days. One 
possible interpretation of these data is that HDC expression is reduced to compensate for 
excessive histamine release, which could contribute to insomnia-like symptoms in the SPS 
model. However, future studies including the measurement of extracellular histamine in the 
hypothalamus using microdialysis would be required to confirm this hypothesis. Additionally, a 
cellular mechanism would have to be elucidated through which excessive histamine release is 
detected resulting in compensatory reductions in HDC expression. Still, this finding suggests that 
antihistaminergic drugs could be useful as hypnotic agents in addressing PTSD-related insomnia. 
This hypothesis is supported by the recent observation that the antihistamine hydroxyzine was 
moderately effective in treating sleep disruptions in PTSD patients (373). 
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 Taken together, our initial validation of the SPS model provides a strong foundation for 
the examination of this and other alternative interventions aimed at preventing or treating PTSD 
symptoms. We have also provided the first evidence that post-trauma systemic administration of 
a selective mGluR5 NAM prevents the development of some PTSD-like symptoms in this model, 
and may show similar promise in the clinical arena. This therapeutic effect was at least partially 
mediated by altering the amount and quality of REM sleep in the aftermath of trauma exposure, 
highlighting the importance of examining sleep-dependent emotional memory consolidation 
during the discovery and development of novel pharmacotherapeutic strategies for the treatment 
of PTSD symptoms. 
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APPENDIX A 
 
POSITIVE MODULATORS OF NMDA RECEPTOR FUNCTION 
 
Methods 
Subjects 
All male Sprague-Dawley rats (Harlan, Indianapolis, IN) used in the present studies were 
housed under a 12 hour light:12 hour dark cycle and given ad libitum access to food and water. 
All animal experiments were approved by the Vanderbilt University Animal Care and Use 
Committee and experimental procedures conformed to guidelines established by the National 
Research Council Guide for the Care and Use of Laboratory Animals. All efforts were made to 
minimize animal suffering and the number of animals used. 
 
Compound 
 VU0409551 was synthesized in house as previously described (366), and dissolved in 
10% Tween 80 vehicle, creating a microsuspension prior to intraperitoneal (i.p.) administration 
at a volume of 2mL/kg. D-cycloserine (DCS) was purchased from Sigma-Aldrich, and fully 
dissolved in saline prior to i.p. administration at a volume of 1mL/kg. ACPPBII was synthesized 
in house as previously described (94), and dissolved in 20% beta-cyclodextrin vehicle, creating a 
suspension prior to i.p. administration at a volume of 3mL/kg. 
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EEG Surgery 
Rats (250-375 grams) were surgically implanted with a telemetric transmitter (4-ET, Data 
Sciences International, St. Paul, MN) for recording EEG, electromyography (EMG), and body 
temperature. Under isoflurane anesthesia (3% induction; 1.5-2.5% maintenance) the transmitter 
was implanted subcutaneously across the back of each rat. Transmitter leads were tunneled 
subcutaneously to the skull. After holes were drilled in the skull, the exposed wires were placed 
in contact with the dura and secured in place with dental cement (Butler Schein, Dublin, OH). 
Three sets of leads were placed bilaterally to record from cortical regions corresponding to the 
frontal, parietal, and occipital cortices (+2 mm, -2 mm, and -6mm anterior-posterior from 
Bregma, respectively and +/- 2 mm lateral to the midline). An additional set of leads was placed 
bilaterally in the nuchal muscles for EMG recording. Rats were individually housed following 
surgery and allowed to recover and acclimate to the recording room for a minimum of 10 days 
prior to testing.  
 
EEG 
Eeach rat was randomized into vehicle, VU0409551 (3, 10, 30 mg/kg, i.p.),  DCS (3, 10, 
30 mg/kg, i.p.), or ACPPBII (1, 3, 10 mg/kg, i.p.) dose groups. Baseline recordings were begun 
at the start of the light phase, then the appropriate compound was administered two hours later, 
and recordings were allowed to continue for the remainder of the twenty-four hour period. In a 
partial crossover design, each rat received two different doses or vehicle, allowing for a 5 day 
washout period between compound administrations. 
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Spontaneous locomotor activity 
 Spontaneous locomotor activity was conducted in open-field chambers (27 × 27 × 20 cm) 
(Hamilton Kinder) equipped with 16 horizontal (x- and y-axes) infrared photobeams. Changes in 
locomotor activity were measured as the number of photobeam breaks per five minutes, and 
were recorded with a Pentium I computer equipped with rat activity monitoring system software 
(Hamilton Kinder). Rats were pretreated with vehicle or ACPPBII, (1, 3, 10 mg/kg, i.p.) then 
placed individually into each chamber 30 minutes later. Locomotor activity was assessed for 
thirty minutes. 
 
In vitro glycine uptake  
 Human choriocarcinoma (JAR) cells (American Type Culture Collection), endogenously 
expressing GlyT1 were cultured in vitro in complete DMEM supplemented with 10% FBS, 2 
mM glutamine, 20 mM HEPES, 0.1 mM nonessential amino acids, 1mM sodiumpyruvate, and 
antibiotic/antimycotic (Life Technolgies ,Carlsbad, CA) at 37 ºC in 5% CO2 in a humidified cell 
incubator. Cells were plated at 20,000 cells per well in 96-well Cytostar-T scintillation 
microplates (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) and cultured for 24 
hours. The culture medium was then aspirated and the cells were washed followed by addition of 
a range of concentrations of ACPPBII, the comparator NFPS, or glycine dissolved in DMSO in 
combination with 10 ul of [14C]glycine. After two hours, each well was washed to remove 
radioactivity from the media, and radioactivity counts present inside the cell due to specific 
glycine uptake were performed using a TopCount (PerkinElmer). Fifty percent inhibitory 
concentrations (IC50) for each compound was determined after performing non-linear regression 
analysis in the statistical software Prism (GraphPad). 
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In vivo pharmacokinetics 
 15min, 1, 3, 8, 12, and 24 hours after ACPPBII or NFPS administration, rats were deeply 
anesthetized with isoflurane, rapidly decapitated, and trunk blood and whole brain was collected. 
Plasma was separated by centrifugation (4000 rcf, 4 °C) and stored at -80 °C until analysis. On 
the day of analysis, frozen whole-mouse brains were weighed and diluted with 1:3 (w/w) parts of 
70:30 isopropanol:water. The mixture was then subjected to mechanical homogenation 
employing a Mini-Beadbeater™ and 1.0 mm Zirconia/Silica Beads (BioSpec Products) followed 
by centrifugation. The sample extraction of plasma (20 μL) or brain homogenate (20 μL) was 
performed by a method based on protein precipitation using three volumes of acetonitrile 
containing an internal standard (50 ng/mL carbamazepine). The samples were centrifuged (3000 
rcf, 5 min) and supernatants transferred and diluted 1:1 (supernatant:water) into a new 96 well 
plate, which was then sealed in preparation for LC/MS/MS analysis.  
 
LC/MS/MS analysis 
 Analysis was performed as previously described (374). 
 
Tissue collection 
Rats were briefly anesthetized with isoflurane, and sacrificed by decapitation thirty 
minutes after i.p. administration of vehicle or ACPPBII (1, 3, 10 mg/kg). Hippocampus, 
amygdala, and PFC were dissected, rapidly frozen on dry ice, and stored at −80 °C for tissue 
neurochemistry experiments. 
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Tissue neurochemistry 
Tissue concentrations of 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) 
were determined by HPLC-ECD as described previously (316).   
 
Fear extinction 
 For contextual CF extinction experiments, rats were placed in the CF chambers described 
above for each component of the experiment. To test the effects of ACPPBII on extinction 
acquisition, rats were trained with the following protocol: habituation to the chamber for one 
minute followed by exposure to four 1s, 0.5mA footshocks with intershock intervals of one 
minute. On each of the subsequent extinction days, rats were returned to the same chamber for 
seven minutes, and their freezing response was recorded in the absence of footshock. The 
compound was dosed thirty minutes prior to each extinction session every day.  
To test the effects of ACPPBII on extinction consolidation, rats were trained with the 
following protocol: habituation to the chamber for three minutes followed by two 4s, 0.8 mA 
footshocks with intershock intervals of 30s and 60s after the last shock.  On each of the 
subsequent extinction days, rats were returned to the same chamber for ten minutes, and their 
freezing response was recorded in the absence of footshock. The compound was dosed 
immediately after each extinction session every day. 
 
Statistical analysis 
For the acute effects of each compound on sleep-wake architecture, and the effect of 
ACPPBII on spontaneous locomotor activity a repeated measures two-way analysis of variance 
(ANOVA) was applied; if significant, a Bonferroni post hoc test was performed with 
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significance defined as P < .05. For the effects of ACPPBII on 5-HT utilization in the amygdala, 
a one-way ANOVA was applied; if significant, a Dunnett’s post hoc test was used with 
significance defined as P < .05.  
 
Results 
VU0409551 increased time spent awake (Figure 30) (time [F11,264 = 31.80, P < 0.0001], 
interaction [F33,264 = 2.02, P = 0.0013]), and decreased NREM sleep (time [F11,264 = 32.98, P 
< .0001], interaction [F11,264 = 2.06, P = .001]) and REM sleep (time [F11,286 = 17.54]). DCS 
had a main effect on time spent in wake (Figure 31) (time [F11,352 = 78.26, P < 0.0001], dose 
[F3,32 = 3.83, P = 0.0188]) and NREM sleep (time [F11,308 = 70.86, P < 0.0001], dose [F3,28 = 
3.77, P = 0.0217]), and acutely increased time spent in REM sleep ) (time [F11,308 = 22.21, P < 
0.0001]). ACPPBII acutely increased time spent in wake (Figure 32) (time [F11,506 = 117.1, P < 
0.0001], interaction [F33,506 = 2.61, P < 0.0001]), and reduced time spent in NREM sleep (time 
[F11,506 = 115.1, P < 0.0001], interaction [F33,506 = 2.00, P = 0.001]) and REM sleep (time 
[F11,506 = 26.32, P < 0.0001], dose [F3,46 = 4.05, P = 0.0123], interaction [F33,506 = 2.74, P < 
0.0001]). 
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Figure 30. VU0409551 increased time spent in wake. ^^ P < 0.01, 3mg/kg vs. Veh; *P < 0.05, 
**P < 0.01, 10 mg/kg vs. Veh; #P < 0.05, ####P < .0001, 30 mg/kg vs. Veh in Bonferroni post 
hoc test. 
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Figure 31. DCS increased time spent in REM sleep. ^ P < 0.05, 3mg/kg vs. Veh; #P < 0.05, 
##P < .01, 30 mg/kg vs. Veh in Bonferroni post hoc test. 
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Figure 32. ACPPBII increased time spent in wake. ^ P < 0.05, 1mg/kg vs. Veh; #P < 0.05, 
##P < .01, 10 mg/kg, ###P < .001, 30 mg/kg vs. Veh in Bonferroni post hoc test. 
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 ACPPBII exhibited an in vitro IC50 of 45 nanomolar (nM) which was similar in potency 
to the prototypical GlyT1 inhibitor NFPS (Figure 33) (IC50 = 24 nM). ACPPBII was similarly 
brain penetrant as well, achieving concentrations well above its in vitro IC50 (Figure 34). 
ACPPBII also increased 5-HT utilization as evidenced by increased 5-HIAA concentrations in 
the amygdala (Figure 35) (F3,26 = 1.55, P = 0.0392) with no change in 5-HT concentration. 
However, ACPPBII also induced adverse motor effects including a reduction in spontaneous 
locomotor activity (Figure 36) (time [F5,125 = 99.5, P < 0.0001], dose [F3,25 = 5.23, P = 
0.0061], interaction [F15,125 = 3.80, P < 0.0001]). Consistent with the observed toxicity of this 
compound, ACPPBII failed to facilitate the extinction of contextual CF (Figure 37). 
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Figure 33. ACPPBII is a potent inhibitor of GlyT1. ACPPBII exhibited a potency of 45nM in 
inhibiting glycine uptake by GlyT1 in an in vitro assay. NFPS exhibited a potency of 24nM.  
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Figure 34. ACPPBII penetrates the central nervous system similar to the prototypical 
GlyT1 inhibitor NFPS. 
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Figure 35. ACPPBII increase 5-HT utilization in the amygdala. *P < 0.05 vs. Veh in 
Dunnett’s post-hoc test. 
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Figure 36. ACPPBII reduces spontaneous locomotor activity. #P < 0.05, ###P < 0.001, 
####P < 0.0001 10mg/kg vs. Veh. 
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Figure 37. ACPPBII did not enhance extinction learning. ACPPBII failed to promote 
reductions in the freezing response when administered before or after context-mediated 
extinction training at 3 or 30mg/kg, i.p. Arrows represent dose times.  
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APPENDIX B 
 
EFFECTS OF TRAUMATIC STRESS ON OREXINERGIC AND HISTAMINERGIC 
SYSTEMS 
 
Methods 
Subjects 
All male Sprague-Dawley rats (Harlan, Indianapolis, IN) used in the present studies were 
housed under a 12 hour light:12 hour dark cycle and given ad libitum access to food and water. 
All animal experiments were approved by the Vanderbilt University Animal Care and Use 
Committee and experimental procedures conformed to guidelines established by the National 
Research Council Guide for the Care and Use of Laboratory Animals. All efforts were made to 
minimize animal suffering and the number of animals used. 
 
Single Prolonged Stress 
SPS was performed according to Liberzon et al. (315). Briefly, rats were restrained for 2 
hours, followed by forced swim for 15 minutes in 24 ⁰C water. Following a 15 minute recovery 
period, rats were exposed to diethyl ether vapor in a bell jar until anesthesia. The SPS model did 
not cause mortality. SPS did illicit hallmarks of the rodent stress response such as porphyrin 
staining of the eyes, and urination and defecation. There were no major individual differences 
observed in these parameters during each experiment, and no inclusion or exclusion criteria were 
applied prior to the start of EEG recordings or tissue collection. SHAM treatment consisted of 
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placement in a novel procedure room for 2 hours followed by brief handling. All animals were 
placed into fresh cages after treatment.  
 
Tissue collection 
For all biochemical endpoints, rats were randomly assigned to SHAM treatment or one of 
three SPS groups (Day 0, 1 or 7). Rats were briefly anesthetized with isoflurane, and sacrificed 
by decapitation either immediately (Day 0), one day (Day 1), or seven days (Day 7) after SPS; 
SHAM rats were sacrificed immediately after SHAM treatment. Hippocampus, amygdala, and 
PFC were dissected, rapidly frozen on dry ice, and stored at −80 °C for tissue mRNA 
experiments.  
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Alterations in mRNA expression levels were measured using Aqueous Micro kits (Life 
Technologies, Grand Island, NY) for RNA extraction, NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE) for RNA quantification, QuantiTect Reverse 
Transcription Kit (QIAGEN, Hilden, Germany) for complementary DNA transcription, CFX96 
Real-Time PCR Detection System (Bio-Rad, Hercules, CA) using primers from TaqMan Gene 
Expression Assays (Life Technologies) for qRT-PCR of rat OxR1, OxR2, and HDC. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control; data are 
presented using the comparative cycle threshold (CT) method normalized to SHAM-treated rats. 
 
Statistical analysis 
For the acute effects of each compound on sleep-wake architecture, and the effect of 
ACPPBII on spontaneous locomotor activity a repeated measures two-way analysis of variance 
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(ANOVA) was applied; if significant, a Bonferroni post hoc test was performed with 
significance defined as P < .05. For the effects of ACPPBII on 5-HT utilization in the amygdala, 
a one-way ANOVA was applied; if significant, a Dunnett’s post hoc test was used with 
significance defined as P < .05.  
 
Results 
SPS increased mRNA concentration of Ox1R in the PFC on Days 1 and 2 after SPS 
(F3,28 = 5.52, P = 0.0042), and on Day 2 in the hippocampus (F3,28 = 3.94, P = 0.0184). SPS 
also increased Ox2R expression in the hippocampus on Day 2 (F3,26 = 3.63, P < 0.0259), but 
had no significant effect in the hypothalamus or amygdala (Figure 37). SPS also caused a 
substantial sustained reduction in mRNA concentration of HDC in the hypothalamus (Figure 38) 
(F3,30 = 4.01, P < 0.0163).  
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Figure 38. SPS caused an increase in mRNA concentration of orexin receptors in the PFC 
and hippocampus. SPS increased mRNA concentration of Ox1R in the PFC on Days 1 and 2 
after SPS, and on Day 2 in the hippocampus. SPS also increased Ox2R expression in the 
hippocampus on Day 2. *P < 0.05, **P < 0.01 vs. SHAM in Dunnett’s post hoc test.  
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Figure 39. SPS caused a decrease in mRNA concentration of HDC in the hypothalamus. *P 
< 0.05 vs. SHAM.  
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